{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Import data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### EMA data from https://www.ema.europa.eu/en/medicines/download-medicine-data#rare-disease-(orphan)-designations-section"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Medicine name</th>\n",
       "      <th>Active substance</th>\n",
       "      <th>Agency product number</th>\n",
       "      <th>Date of first decision</th>\n",
       "      <th>Disease / condition</th>\n",
       "      <th>EU designation number</th>\n",
       "      <th>Status of orphan designation</th>\n",
       "      <th>First published</th>\n",
       "      <th>Revision date</th>\n",
       "      <th>URL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>494</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Etilefrine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2002-11-13 01:00:00</td>\n",
       "      <td>Treatment of low-flow priapism</td>\n",
       "      <td>EU/3/02/122</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2002-12-13 01:09:21</td>\n",
       "      <td>2013-06-25 16:15:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Recombinant glycoprotein gp350 of Epstein-Barr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2002-10-22 00:00:00</td>\n",
       "      <td>Prevention of post-transplantation lympho-prol...</td>\n",
       "      <td>EU/3/02/118</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2002-12-17 01:09:00</td>\n",
       "      <td>2002-12-17 01:09:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>631</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Iodine (131I) chimeric IgG monoclonal antibody...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2002-03-19 01:00:00</td>\n",
       "      <td>Treatment of renal-cell carcinoma</td>\n",
       "      <td>EU/3/02/095</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2003-01-06 02:00:00</td>\n",
       "      <td>2014-06-18 18:45:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1054</th>\n",
       "      <td>Cerepro,</td>\n",
       "      <td>Adenovirus-mediated herpes-simplex-virus thymi...</td>\n",
       "      <td>EMEA/H/C/000694</td>\n",
       "      <td>2002-02-06 01:00:00</td>\n",
       "      <td>Treatment of high-grade glioma with subsequent...</td>\n",
       "      <td>EU/3/01/083</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2003-01-06 02:00:00</td>\n",
       "      <td>2016-08-15 18:40:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2117</th>\n",
       "      <td>NaN</td>\n",
       "      <td>nitisinone</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2002-03-13 01:00:00</td>\n",
       "      <td>Treatment of alkaptonuria</td>\n",
       "      <td>EU/3/02/096</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2003-01-06 02:00:00</td>\n",
       "      <td>2020-04-01 15:50:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2284</th>\n",
       "      <td>NaN</td>\n",
       "      <td>(+)-Epicatechin</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>Treatment of Becker muscular dystrophy</td>\n",
       "      <td>EU/3/20/2293</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-23 15:45:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2285</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Sodium cromoglicate</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>Treatment of idiopathic pulmonary fibrosis</td>\n",
       "      <td>EU/3/20/2294</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-23 15:45:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2286</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Lys40(NODAGA-68Ga)NH2-exendin-4</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>Diagnosis of insulinoma</td>\n",
       "      <td>EU/3/20/2295</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-24 12:32:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2287</th>\n",
       "      <td>NaN</td>\n",
       "      <td>axicabtagene ciloleucel</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>Treatment of marginal zone lymphoma</td>\n",
       "      <td>EU/3/20/2296</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-24 14:40:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2288</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Adeno-associated virus serotype HSC15 expressi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>treatment of metachromatic leukodystrophy</td>\n",
       "      <td>EU/3/20/2297</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-24 14:40:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2327 rows × 10 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Medicine name                                   Active substance  \\\n",
       "494            NaN                                         Etilefrine   \n",
       "65             NaN  Recombinant glycoprotein gp350 of Epstein-Barr...   \n",
       "631            NaN  Iodine (131I) chimeric IgG monoclonal antibody...   \n",
       "1054     Cerepro,   Adenovirus-mediated herpes-simplex-virus thymi...   \n",
       "2117           NaN                                         nitisinone   \n",
       "...            ...                                                ...   \n",
       "2284           NaN                                    (+)-Epicatechin   \n",
       "2285           NaN                                Sodium cromoglicate   \n",
       "2286           NaN                    Lys40(NODAGA-68Ga)NH2-exendin-4   \n",
       "2287           NaN                            axicabtagene ciloleucel   \n",
       "2288           NaN  Adeno-associated virus serotype HSC15 expressi...   \n",
       "\n",
       "     Agency product number Date of first decision  \\\n",
       "494                    NaN    2002-11-13 01:00:00   \n",
       "65                     NaN    2002-10-22 00:00:00   \n",
       "631                    NaN    2002-03-19 01:00:00   \n",
       "1054       EMEA/H/C/000694    2002-02-06 01:00:00   \n",
       "2117                   NaN    2002-03-13 01:00:00   \n",
       "...                    ...                    ...   \n",
       "2284                   NaN    2020-06-26 00:00:00   \n",
       "2285                   NaN    2020-06-26 00:00:00   \n",
       "2286                   NaN    2020-06-26 00:00:00   \n",
       "2287                   NaN    2020-06-26 00:00:00   \n",
       "2288                   NaN    2020-06-26 00:00:00   \n",
       "\n",
       "                                    Disease / condition EU designation number  \\\n",
       "494                      Treatment of low-flow priapism           EU/3/02/122   \n",
       "65    Prevention of post-transplantation lympho-prol...           EU/3/02/118   \n",
       "631                   Treatment of renal-cell carcinoma           EU/3/02/095   \n",
       "1054  Treatment of high-grade glioma with subsequent...           EU/3/01/083   \n",
       "2117                          Treatment of alkaptonuria           EU/3/02/096   \n",
       "...                                                 ...                   ...   \n",
       "2284             Treatment of Becker muscular dystrophy          EU/3/20/2293   \n",
       "2285         Treatment of idiopathic pulmonary fibrosis          EU/3/20/2294   \n",
       "2286                            Diagnosis of insulinoma          EU/3/20/2295   \n",
       "2287                Treatment of marginal zone lymphoma          EU/3/20/2296   \n",
       "2288          treatment of metachromatic leukodystrophy          EU/3/20/2297   \n",
       "\n",
       "     Status of orphan designation     First published       Revision date  \\\n",
       "494                      Positive 2002-12-13 01:09:21 2013-06-25 16:15:00   \n",
       "65                       Positive 2002-12-17 01:09:00 2002-12-17 01:09:00   \n",
       "631                     Withdrawn 2003-01-06 02:00:00 2014-06-18 18:45:00   \n",
       "1054                     Positive 2003-01-06 02:00:00 2016-08-15 18:40:00   \n",
       "2117                    Withdrawn 2003-01-06 02:00:00 2020-04-01 15:50:00   \n",
       "...                           ...                 ...                 ...   \n",
       "2284                     Positive 2020-09-23 15:45:00                 NaT   \n",
       "2285                     Positive 2020-09-23 15:45:00                 NaT   \n",
       "2286                     Positive 2020-09-24 12:32:00                 NaT   \n",
       "2287                     Positive 2020-09-24 14:40:00                 NaT   \n",
       "2288                     Positive 2020-09-24 14:40:00                 NaT   \n",
       "\n",
       "                                                    URL  \n",
       "494   https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "65    https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "631   https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "1054  https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "2117  https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "...                                                 ...  \n",
       "2284  https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "2285  https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "2286  https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "2287  https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "2288  https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "\n",
       "[2327 rows x 10 columns]"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import numpy as np\n",
    "import pandas as pd\n",
    "\n",
    "ema_data = pd.read_excel('data/Medicines_output_orphan_designations.xlsx', header=8)\n",
    "ema_data.sort_values(by='First published', inplace=True)\n",
    "ema_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### How many 'Positives', 'Withdrawn', 'Negative?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1698"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(ema_data[ema_data['Status of orphan designation'] == 'Positive'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "543"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(ema_data[ema_data['Status of orphan designation'] == 'Withdrawn'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "30"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(ema_data[ema_data['Status of orphan designation'] == 'Negative'])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### How many 'NaT' Revision date entries\n",
    "Entries with NaT revision date may not have been passed on to the EC (NaT means missing entry)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "209"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Get this weird NaT value\n",
    "NaT = type(ema_data.iloc[2288]['Revision date'])\n",
    "len(ema_data[ema_data['Revision date'].isnull()])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### How many of those are positive (is this the missing fraction in comparison to the EU # matched dataset)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/david/Documents/SABS/DPhil/erlotinib/venv/lib/python3.7/site-packages/ipykernel_launcher.py:1: UserWarning: Boolean Series key will be reindexed to match DataFrame index.\n",
      "  \"\"\"Entry point for launching an IPython kernel.\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "204"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(ema_data[ema_data['Status of orphan designation'] == 'Positive'][ema_data['Revision date'].isnull()])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### European comission data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>EU designation number</th>\n",
       "      <th>Product</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Sponsor</th>\n",
       "      <th>Designation date</th>\n",
       "      <th>Tradename - EU product # - Implemented on</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>EU/3/20/2351</td>\n",
       "      <td>Adeno-associated virus serotype 5 containing t...</td>\n",
       "      <td>Treatment of RDH12 mutation associated retinal...</td>\n",
       "      <td>MeiraGTx B.V.</td>\n",
       "      <td>19 Oct 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>EU/3/20/2350</td>\n",
       "      <td>Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-me...</td>\n",
       "      <td>Treatment of hypoparathyroidism</td>\n",
       "      <td>Ascendis Pharma Bone Diseases A/S</td>\n",
       "      <td>19 Oct 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>EU/3/20/2349</td>\n",
       "      <td>Miglustat</td>\n",
       "      <td>Treatment of neuronal ceroid lipofuscinosis</td>\n",
       "      <td>Theranexus S.A.S.</td>\n",
       "      <td>19 Oct 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>EU/3/20/2348</td>\n",
       "      <td>Poly(oxy-1,2-ethanediyl), alpha-(carboxymethyl...</td>\n",
       "      <td>Treatment of homocystinuria</td>\n",
       "      <td>Aeglea Biotherapeutics UK Limited</td>\n",
       "      <td>19 Oct 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>EU/3/20/2347</td>\n",
       "      <td>Trehalose</td>\n",
       "      <td>Treatment of neuronal ceroid lipofuscinosis</td>\n",
       "      <td>Theranexus S.A.S.</td>\n",
       "      <td>19 Oct 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1735</th>\n",
       "      <td>EU/3/01/034</td>\n",
       "      <td>Gusperimus trihydrochloride</td>\n",
       "      <td>Treatment of Wegener’s granulomatosis</td>\n",
       "      <td>Nordic Group B.V.</td>\n",
       "      <td>29 Mar 2001</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1736</th>\n",
       "      <td>EU/3/01/028</td>\n",
       "      <td>Inolimomab</td>\n",
       "      <td>Treatment of Graft versus Host Disease</td>\n",
       "      <td>Elsalys Biotech SA</td>\n",
       "      <td>05 Mar 2001</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1737</th>\n",
       "      <td>EU/3/01/026</td>\n",
       "      <td>L-Lysine-N-acetyl-L-cysteinate</td>\n",
       "      <td>Treatment of cystic fibrosis</td>\n",
       "      <td>LABORATOIRES SMB SA</td>\n",
       "      <td>14 Feb 2001</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1738</th>\n",
       "      <td>EU/3/00/013</td>\n",
       "      <td>Ethyl Eicosopentaenoate</td>\n",
       "      <td>Treatment of Huntington's disease</td>\n",
       "      <td>Amarin Neuroscience Limited</td>\n",
       "      <td>29 Dec 2000</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1739</th>\n",
       "      <td>EU/3/00/005</td>\n",
       "      <td>Gemtuzumab Ozogamicin</td>\n",
       "      <td>Treatment of acute myeloid leukaemia</td>\n",
       "      <td>Pfizer Europe MA EEIG</td>\n",
       "      <td>18 Oct 2000</td>\n",
       "      <td>Mylotarg - \\nEU/1/18/1277 - \\n23 Apr 2018</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1740 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     EU designation number                                            Product  \\\n",
       "0             EU/3/20/2351  Adeno-associated virus serotype 5 containing t...   \n",
       "1             EU/3/20/2350  Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-me...   \n",
       "2             EU/3/20/2349                                          Miglustat   \n",
       "3             EU/3/20/2348  Poly(oxy-1,2-ethanediyl), alpha-(carboxymethyl...   \n",
       "4             EU/3/20/2347                                          Trehalose   \n",
       "...                    ...                                                ...   \n",
       "1735           EU/3/01/034                        Gusperimus trihydrochloride   \n",
       "1736           EU/3/01/028                                         Inolimomab   \n",
       "1737           EU/3/01/026                     L-Lysine-N-acetyl-L-cysteinate   \n",
       "1738           EU/3/00/013                            Ethyl Eicosopentaenoate   \n",
       "1739           EU/3/00/005                              Gemtuzumab Ozogamicin   \n",
       "\n",
       "                                             Indication  \\\n",
       "0     Treatment of RDH12 mutation associated retinal...   \n",
       "1                       Treatment of hypoparathyroidism   \n",
       "2           Treatment of neuronal ceroid lipofuscinosis   \n",
       "3                           Treatment of homocystinuria   \n",
       "4           Treatment of neuronal ceroid lipofuscinosis   \n",
       "...                                                 ...   \n",
       "1735              Treatment of Wegener’s granulomatosis   \n",
       "1736             Treatment of Graft versus Host Disease   \n",
       "1737                       Treatment of cystic fibrosis   \n",
       "1738                  Treatment of Huntington's disease   \n",
       "1739               Treatment of acute myeloid leukaemia   \n",
       "\n",
       "                                Sponsor Designation date  \\\n",
       "0                         MeiraGTx B.V.      19 Oct 2020   \n",
       "1     Ascendis Pharma Bone Diseases A/S      19 Oct 2020   \n",
       "2                     Theranexus S.A.S.      19 Oct 2020   \n",
       "3     Aeglea Biotherapeutics UK Limited      19 Oct 2020   \n",
       "4                     Theranexus S.A.S.      19 Oct 2020   \n",
       "...                                 ...              ...   \n",
       "1735                  Nordic Group B.V.      29 Mar 2001   \n",
       "1736                 Elsalys Biotech SA      05 Mar 2001   \n",
       "1737                LABORATOIRES SMB SA      14 Feb 2001   \n",
       "1738        Amarin Neuroscience Limited      29 Dec 2000   \n",
       "1739              Pfizer Europe MA EEIG      18 Oct 2000   \n",
       "\n",
       "      Tradename - EU product # - Implemented on  \n",
       "0                                             -  \n",
       "1                                             -  \n",
       "2                                             -  \n",
       "3                                             -  \n",
       "4                                             -  \n",
       "...                                         ...  \n",
       "1735                                          -  \n",
       "1736                                          -  \n",
       "1737                                          -  \n",
       "1738                                          -  \n",
       "1739  Mylotarg - \\nEU/1/18/1277 - \\n23 Apr 2018  \n",
       "\n",
       "[1740 rows x 6 columns]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ec_data = pd.read_csv('data/orphan.csv', header=2)\n",
    "ec_data = ec_data.rename(columns={'EU #': 'EU designation number'})\n",
    "ec_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Crossref entries in EMA to EC using the EU designation number"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Medicine name</th>\n",
       "      <th>Active substance</th>\n",
       "      <th>Agency product number</th>\n",
       "      <th>Date of first decision</th>\n",
       "      <th>Disease / condition</th>\n",
       "      <th>EU designation number</th>\n",
       "      <th>Status of orphan designation</th>\n",
       "      <th>First published</th>\n",
       "      <th>Revision date</th>\n",
       "      <th>URL</th>\n",
       "      <th>Product</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Sponsor</th>\n",
       "      <th>Designation date</th>\n",
       "      <th>Tradename - EU product # - Implemented on</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Etilefrine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2002-11-13 01:00:00</td>\n",
       "      <td>Treatment of low-flow priapism</td>\n",
       "      <td>EU/3/02/122</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2002-12-13 01:09:21</td>\n",
       "      <td>2013-06-25 16:15:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>Etilefrin</td>\n",
       "      <td>Treatment of low flow priapism</td>\n",
       "      <td>Laboratoires SERB</td>\n",
       "      <td>13 Nov 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Recombinant glycoprotein gp350 of Epstein-Barr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2002-10-22 00:00:00</td>\n",
       "      <td>Prevention of post-transplantation lympho-prol...</td>\n",
       "      <td>EU/3/02/118</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2002-12-17 01:09:00</td>\n",
       "      <td>2002-12-17 01:09:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>Recombinant glycoprotein gp350 of Epstein-Barr...</td>\n",
       "      <td>Prevention of post transplantation lympho-prol...</td>\n",
       "      <td>Henogen S.A.</td>\n",
       "      <td>22 Oct 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Cerepro,</td>\n",
       "      <td>Adenovirus-mediated herpes-simplex-virus thymi...</td>\n",
       "      <td>EMEA/H/C/000694</td>\n",
       "      <td>2002-02-06 01:00:00</td>\n",
       "      <td>Treatment of high-grade glioma with subsequent...</td>\n",
       "      <td>EU/3/01/083</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2003-01-06 02:00:00</td>\n",
       "      <td>2016-08-15 18:40:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>Adenovirus-mediated Herpes simplex Virus-thymi...</td>\n",
       "      <td>Treatment of high-grade glioma with subsequent...</td>\n",
       "      <td>Boyd Consultants Limited</td>\n",
       "      <td>06 Feb 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Prohippur,</td>\n",
       "      <td>Benzoic acid, sodium salt</td>\n",
       "      <td>EMEA/H/C/004150</td>\n",
       "      <td>2002-09-11 00:00:00</td>\n",
       "      <td>Treatment of non-ketotic hyperglycinaemia</td>\n",
       "      <td>EU/3/02/111</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2003-01-08 01:09:00</td>\n",
       "      <td>2003-01-08 01:09:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>Benzoic acid, sodium salt</td>\n",
       "      <td>Treatment of non-ketotic hyperglycinaemia</td>\n",
       "      <td>Ethicare GmbH</td>\n",
       "      <td>11 Sep 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Autologous Renal Cell Tumour Vaccine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2002-10-21 00:00:00</td>\n",
       "      <td>Treatment of renal-cell carcinoma</td>\n",
       "      <td>EU/3/02/116</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2003-01-08 01:09:00</td>\n",
       "      <td>2003-01-08 01:09:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>Autologous renal cell tumor vaccine</td>\n",
       "      <td>Treatment of renal cell carcinoma</td>\n",
       "      <td>Liponova GmbH</td>\n",
       "      <td>21 Oct 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1663</th>\n",
       "      <td>NaN</td>\n",
       "      <td>(+)-Epicatechin</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>Treatment of Becker muscular dystrophy</td>\n",
       "      <td>EU/3/20/2293</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-23 15:45:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>(+)-epicatechin</td>\n",
       "      <td>Treatment of Becker muscular dystrophy</td>\n",
       "      <td>MWB Consulting S.A.R.L.</td>\n",
       "      <td>26 Jun 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1664</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Sodium cromoglicate</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>Treatment of idiopathic pulmonary fibrosis</td>\n",
       "      <td>EU/3/20/2294</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-23 15:45:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>Sodium cromoglicate</td>\n",
       "      <td>Treatment of idiopathic pulmonary fibrosis</td>\n",
       "      <td>IQVIA RDS Spain S.L.</td>\n",
       "      <td>26 Jun 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1665</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Lys40(NODAGA-68Ga)NH2-exendin-4</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>Diagnosis of insulinoma</td>\n",
       "      <td>EU/3/20/2295</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-24 12:32:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>Lys40(NODAGA-68Ga)NH2-exendin-4</td>\n",
       "      <td>Diagnosis of insulinoma</td>\n",
       "      <td>Stichting Katholieke Universiteit</td>\n",
       "      <td>26 Jun 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1666</th>\n",
       "      <td>NaN</td>\n",
       "      <td>axicabtagene ciloleucel</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>Treatment of marginal zone lymphoma</td>\n",
       "      <td>EU/3/20/2296</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-24 14:40:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>Axicabtagene ciloleucel</td>\n",
       "      <td>Treatment of marginal zone lymphoma</td>\n",
       "      <td>Kite Pharma EU B.V.</td>\n",
       "      <td>26 Jun 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1667</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Adeno-associated virus serotype HSC15 expressi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>treatment of metachromatic leukodystrophy</td>\n",
       "      <td>EU/3/20/2297</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-24 14:40:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>Adeno-associated virus serotype HSC15 expressi...</td>\n",
       "      <td>Treatment of metachromatic leukodystrophy</td>\n",
       "      <td>Yes Pharmaceutical Development Services GmbH</td>\n",
       "      <td>26 Jun 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1668 rows × 15 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Medicine name                                   Active substance  \\\n",
       "0              NaN                                         Etilefrine   \n",
       "1              NaN  Recombinant glycoprotein gp350 of Epstein-Barr...   \n",
       "2        Cerepro,   Adenovirus-mediated herpes-simplex-virus thymi...   \n",
       "3      Prohippur,                           Benzoic acid, sodium salt   \n",
       "4              NaN               Autologous Renal Cell Tumour Vaccine   \n",
       "...            ...                                                ...   \n",
       "1663           NaN                                    (+)-Epicatechin   \n",
       "1664           NaN                                Sodium cromoglicate   \n",
       "1665           NaN                    Lys40(NODAGA-68Ga)NH2-exendin-4   \n",
       "1666           NaN                            axicabtagene ciloleucel   \n",
       "1667           NaN  Adeno-associated virus serotype HSC15 expressi...   \n",
       "\n",
       "     Agency product number Date of first decision  \\\n",
       "0                      NaN    2002-11-13 01:00:00   \n",
       "1                      NaN    2002-10-22 00:00:00   \n",
       "2          EMEA/H/C/000694    2002-02-06 01:00:00   \n",
       "3          EMEA/H/C/004150    2002-09-11 00:00:00   \n",
       "4                      NaN    2002-10-21 00:00:00   \n",
       "...                    ...                    ...   \n",
       "1663                   NaN    2020-06-26 00:00:00   \n",
       "1664                   NaN    2020-06-26 00:00:00   \n",
       "1665                   NaN    2020-06-26 00:00:00   \n",
       "1666                   NaN    2020-06-26 00:00:00   \n",
       "1667                   NaN    2020-06-26 00:00:00   \n",
       "\n",
       "                                    Disease / condition EU designation number  \\\n",
       "0                        Treatment of low-flow priapism           EU/3/02/122   \n",
       "1     Prevention of post-transplantation lympho-prol...           EU/3/02/118   \n",
       "2     Treatment of high-grade glioma with subsequent...           EU/3/01/083   \n",
       "3             Treatment of non-ketotic hyperglycinaemia           EU/3/02/111   \n",
       "4                     Treatment of renal-cell carcinoma           EU/3/02/116   \n",
       "...                                                 ...                   ...   \n",
       "1663             Treatment of Becker muscular dystrophy          EU/3/20/2293   \n",
       "1664         Treatment of idiopathic pulmonary fibrosis          EU/3/20/2294   \n",
       "1665                            Diagnosis of insulinoma          EU/3/20/2295   \n",
       "1666                Treatment of marginal zone lymphoma          EU/3/20/2296   \n",
       "1667          treatment of metachromatic leukodystrophy          EU/3/20/2297   \n",
       "\n",
       "     Status of orphan designation     First published       Revision date  \\\n",
       "0                        Positive 2002-12-13 01:09:21 2013-06-25 16:15:00   \n",
       "1                        Positive 2002-12-17 01:09:00 2002-12-17 01:09:00   \n",
       "2                        Positive 2003-01-06 02:00:00 2016-08-15 18:40:00   \n",
       "3                        Positive 2003-01-08 01:09:00 2003-01-08 01:09:00   \n",
       "4                        Positive 2003-01-08 01:09:00 2003-01-08 01:09:00   \n",
       "...                           ...                 ...                 ...   \n",
       "1663                     Positive 2020-09-23 15:45:00                 NaT   \n",
       "1664                     Positive 2020-09-23 15:45:00                 NaT   \n",
       "1665                     Positive 2020-09-24 12:32:00                 NaT   \n",
       "1666                     Positive 2020-09-24 14:40:00                 NaT   \n",
       "1667                     Positive 2020-09-24 14:40:00                 NaT   \n",
       "\n",
       "                                                    URL  \\\n",
       "0     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "2     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "3     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "4     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "...                                                 ...   \n",
       "1663  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1664  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1665  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1666  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1667  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "\n",
       "                                                Product  \\\n",
       "0                                             Etilefrin   \n",
       "1     Recombinant glycoprotein gp350 of Epstein-Barr...   \n",
       "2     Adenovirus-mediated Herpes simplex Virus-thymi...   \n",
       "3                             Benzoic acid, sodium salt   \n",
       "4                   Autologous renal cell tumor vaccine   \n",
       "...                                                 ...   \n",
       "1663                                    (+)-epicatechin   \n",
       "1664                                Sodium cromoglicate   \n",
       "1665                    Lys40(NODAGA-68Ga)NH2-exendin-4   \n",
       "1666                            Axicabtagene ciloleucel   \n",
       "1667  Adeno-associated virus serotype HSC15 expressi...   \n",
       "\n",
       "                                             Indication  \\\n",
       "0                        Treatment of low flow priapism   \n",
       "1     Prevention of post transplantation lympho-prol...   \n",
       "2     Treatment of high-grade glioma with subsequent...   \n",
       "3             Treatment of non-ketotic hyperglycinaemia   \n",
       "4                     Treatment of renal cell carcinoma   \n",
       "...                                                 ...   \n",
       "1663             Treatment of Becker muscular dystrophy   \n",
       "1664         Treatment of idiopathic pulmonary fibrosis   \n",
       "1665                            Diagnosis of insulinoma   \n",
       "1666                Treatment of marginal zone lymphoma   \n",
       "1667          Treatment of metachromatic leukodystrophy   \n",
       "\n",
       "                                           Sponsor Designation date  \\\n",
       "0                                Laboratoires SERB      13 Nov 2002   \n",
       "1                                     Henogen S.A.      22 Oct 2002   \n",
       "2                         Boyd Consultants Limited      06 Feb 2002   \n",
       "3                                    Ethicare GmbH      11 Sep 2002   \n",
       "4                                    Liponova GmbH      21 Oct 2002   \n",
       "...                                            ...              ...   \n",
       "1663                       MWB Consulting S.A.R.L.      26 Jun 2020   \n",
       "1664                          IQVIA RDS Spain S.L.      26 Jun 2020   \n",
       "1665             Stichting Katholieke Universiteit      26 Jun 2020   \n",
       "1666                           Kite Pharma EU B.V.      26 Jun 2020   \n",
       "1667  Yes Pharmaceutical Development Services GmbH      26 Jun 2020   \n",
       "\n",
       "     Tradename - EU product # - Implemented on  \n",
       "0                                            -  \n",
       "1                                            -  \n",
       "2                                            -  \n",
       "3                                            -  \n",
       "4                                            -  \n",
       "...                                        ...  \n",
       "1663                                         -  \n",
       "1664                                         -  \n",
       "1665                                         -  \n",
       "1666                                         -  \n",
       "1667                                         -  \n",
       "\n",
       "[1668 rows x 15 columns]"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matched_data = pd.merge(ema_data, ec_data, how='inner', on=['EU designation number'])\n",
    "matched_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Check the orphan status of matched designations"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Positive', 'Withdrawn'], dtype=object)"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matched_data['Status of orphan designation'].unique()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### How many are 'Withdrawn'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Medicine name</th>\n",
       "      <th>Active substance</th>\n",
       "      <th>Agency product number</th>\n",
       "      <th>Date of first decision</th>\n",
       "      <th>Disease / condition</th>\n",
       "      <th>EU designation number</th>\n",
       "      <th>Status of orphan designation</th>\n",
       "      <th>First published</th>\n",
       "      <th>Revision date</th>\n",
       "      <th>URL</th>\n",
       "      <th>Product</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Sponsor</th>\n",
       "      <th>Designation date</th>\n",
       "      <th>Tradename - EU product # - Implemented on</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1009</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Live attenuated Listeria monocytogenes delta a...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2015-12-14 01:00:00</td>\n",
       "      <td>Treatment of malignant mesothelioma</td>\n",
       "      <td>EU/3/15/1594</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2016-02-03 17:30:00</td>\n",
       "      <td>2020-01-13 10:41:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>Live attenuated Listeria monocytogenes delta a...</td>\n",
       "      <td>Treatment of malignant mesothelioma</td>\n",
       "      <td>Aduro Biotech Holdings, Europe B.V.</td>\n",
       "      <td>14 Dec 2015</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     Medicine name                                   Active substance  \\\n",
       "1009           NaN  Live attenuated Listeria monocytogenes delta a...   \n",
       "\n",
       "     Agency product number Date of first decision  \\\n",
       "1009                   NaN    2015-12-14 01:00:00   \n",
       "\n",
       "                      Disease / condition EU designation number  \\\n",
       "1009  Treatment of malignant mesothelioma          EU/3/15/1594   \n",
       "\n",
       "     Status of orphan designation     First published       Revision date  \\\n",
       "1009                    Withdrawn 2016-02-03 17:30:00 2020-01-13 10:41:00   \n",
       "\n",
       "                                                    URL  \\\n",
       "1009  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "\n",
       "                                                Product  \\\n",
       "1009  Live attenuated Listeria monocytogenes delta a...   \n",
       "\n",
       "                               Indication  \\\n",
       "1009  Treatment of malignant mesothelioma   \n",
       "\n",
       "                                  Sponsor Designation date  \\\n",
       "1009  Aduro Biotech Holdings, Europe B.V.      14 Dec 2015   \n",
       "\n",
       "     Tradename - EU product # - Implemented on  \n",
       "1009                                         -  "
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matched_data[matched_data['Status of orphan designation'] == 'Withdrawn']"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Get entries where 'Product' and 'Active substances' coincide"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Medicine name</th>\n",
       "      <th>Active substance</th>\n",
       "      <th>Agency product number</th>\n",
       "      <th>Date of first decision</th>\n",
       "      <th>Disease / condition</th>\n",
       "      <th>EU designation number</th>\n",
       "      <th>Status of orphan designation</th>\n",
       "      <th>First published</th>\n",
       "      <th>Revision date</th>\n",
       "      <th>URL</th>\n",
       "      <th>Product</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Sponsor</th>\n",
       "      <th>Designation date</th>\n",
       "      <th>Tradename - EU product # - Implemented on</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NaN</td>\n",
       "      <td>recombinant glycoprotein gp350 of epstein-barr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2002-10-22 00:00:00</td>\n",
       "      <td>Prevention of post-transplantation lympho-prol...</td>\n",
       "      <td>EU/3/02/118</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2002-12-17 01:09:00</td>\n",
       "      <td>2002-12-17 01:09:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>recombinant glycoprotein gp350 of epstein-barr...</td>\n",
       "      <td>Prevention of post transplantation lympho-prol...</td>\n",
       "      <td>Henogen S.A.</td>\n",
       "      <td>22 Oct 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Prohippur,</td>\n",
       "      <td>benzoic acid, sodium salt</td>\n",
       "      <td>EMEA/H/C/004150</td>\n",
       "      <td>2002-09-11 00:00:00</td>\n",
       "      <td>Treatment of non-ketotic hyperglycinaemia</td>\n",
       "      <td>EU/3/02/111</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2003-01-08 01:09:00</td>\n",
       "      <td>2003-01-08 01:09:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>benzoic acid, sodium salt</td>\n",
       "      <td>Treatment of non-ketotic hyperglycinaemia</td>\n",
       "      <td>Ethicare GmbH</td>\n",
       "      <td>11 Sep 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NaN</td>\n",
       "      <td>thymalfasin</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2002-07-30 02:00:00</td>\n",
       "      <td>Treatment of hepatocellular carcinoma</td>\n",
       "      <td>EU/3/02/110</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2003-01-08 01:09:21</td>\n",
       "      <td>2003-01-08 01:09:21</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>thymalfasin</td>\n",
       "      <td>Treatment of hepatocellular carcinoma</td>\n",
       "      <td>SciClone Pharmaceuticals Italy S.r.l</td>\n",
       "      <td>30 Jul 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NexoBrid,</td>\n",
       "      <td>purified bromelain</td>\n",
       "      <td>EMEA/H/C/002246</td>\n",
       "      <td>2002-07-30 02:00:00</td>\n",
       "      <td>Treatment of partial deep dermal and full-thic...</td>\n",
       "      <td>EU/3/02/107</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2003-01-08 02:00:00</td>\n",
       "      <td>2013-09-19 12:00:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>purified bromelain</td>\n",
       "      <td>Treatment of partial deep dermal and full thic...</td>\n",
       "      <td>MediWound Germany GmbH</td>\n",
       "      <td>30 Jul 2002</td>\n",
       "      <td>NexoBrid - \\nEU/1/12/803 - \\n20 Dec 2012</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Voraxaze,</td>\n",
       "      <td>carboxypeptidase g2</td>\n",
       "      <td>EMEA/H/C/000681</td>\n",
       "      <td>2003-02-03 01:00:00</td>\n",
       "      <td>Adjunctive treatment in patients at risk of me...</td>\n",
       "      <td>EU/3/02/128</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2003-02-17 02:00:00</td>\n",
       "      <td>2020-04-02 09:20:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>carboxypeptidase g2</td>\n",
       "      <td>Adjunctive treatment in patients at risk of me...</td>\n",
       "      <td>Protherics Medicines Development Europe B.V.</td>\n",
       "      <td>03 Feb 2003</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1663</th>\n",
       "      <td>NaN</td>\n",
       "      <td>(+)-epicatechin</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>Treatment of Becker muscular dystrophy</td>\n",
       "      <td>EU/3/20/2293</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-23 15:45:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>(+)-epicatechin</td>\n",
       "      <td>Treatment of Becker muscular dystrophy</td>\n",
       "      <td>MWB Consulting S.A.R.L.</td>\n",
       "      <td>26 Jun 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1664</th>\n",
       "      <td>NaN</td>\n",
       "      <td>sodium cromoglicate</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>Treatment of idiopathic pulmonary fibrosis</td>\n",
       "      <td>EU/3/20/2294</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-23 15:45:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>sodium cromoglicate</td>\n",
       "      <td>Treatment of idiopathic pulmonary fibrosis</td>\n",
       "      <td>IQVIA RDS Spain S.L.</td>\n",
       "      <td>26 Jun 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1665</th>\n",
       "      <td>NaN</td>\n",
       "      <td>lys40(nodaga-68ga)nh2-exendin-4</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>Diagnosis of insulinoma</td>\n",
       "      <td>EU/3/20/2295</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-24 12:32:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>lys40(nodaga-68ga)nh2-exendin-4</td>\n",
       "      <td>Diagnosis of insulinoma</td>\n",
       "      <td>Stichting Katholieke Universiteit</td>\n",
       "      <td>26 Jun 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1666</th>\n",
       "      <td>NaN</td>\n",
       "      <td>axicabtagene ciloleucel</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>Treatment of marginal zone lymphoma</td>\n",
       "      <td>EU/3/20/2296</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-24 14:40:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>axicabtagene ciloleucel</td>\n",
       "      <td>Treatment of marginal zone lymphoma</td>\n",
       "      <td>Kite Pharma EU B.V.</td>\n",
       "      <td>26 Jun 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1667</th>\n",
       "      <td>NaN</td>\n",
       "      <td>adeno-associated virus serotype hsc15 expressi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>treatment of metachromatic leukodystrophy</td>\n",
       "      <td>EU/3/20/2297</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-24 14:40:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>adeno-associated virus serotype hsc15 expressi...</td>\n",
       "      <td>Treatment of metachromatic leukodystrophy</td>\n",
       "      <td>Yes Pharmaceutical Development Services GmbH</td>\n",
       "      <td>26 Jun 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1357 rows × 15 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Medicine name                                   Active substance  \\\n",
       "1              NaN  recombinant glycoprotein gp350 of epstein-barr...   \n",
       "3      Prohippur,                           benzoic acid, sodium salt   \n",
       "5              NaN                                        thymalfasin   \n",
       "8       NexoBrid,                                  purified bromelain   \n",
       "10      Voraxaze,                                 carboxypeptidase g2   \n",
       "...            ...                                                ...   \n",
       "1663           NaN                                    (+)-epicatechin   \n",
       "1664           NaN                                sodium cromoglicate   \n",
       "1665           NaN                    lys40(nodaga-68ga)nh2-exendin-4   \n",
       "1666           NaN                            axicabtagene ciloleucel   \n",
       "1667           NaN  adeno-associated virus serotype hsc15 expressi...   \n",
       "\n",
       "     Agency product number Date of first decision  \\\n",
       "1                      NaN    2002-10-22 00:00:00   \n",
       "3          EMEA/H/C/004150    2002-09-11 00:00:00   \n",
       "5                      NaN    2002-07-30 02:00:00   \n",
       "8          EMEA/H/C/002246    2002-07-30 02:00:00   \n",
       "10         EMEA/H/C/000681    2003-02-03 01:00:00   \n",
       "...                    ...                    ...   \n",
       "1663                   NaN    2020-06-26 00:00:00   \n",
       "1664                   NaN    2020-06-26 00:00:00   \n",
       "1665                   NaN    2020-06-26 00:00:00   \n",
       "1666                   NaN    2020-06-26 00:00:00   \n",
       "1667                   NaN    2020-06-26 00:00:00   \n",
       "\n",
       "                                    Disease / condition EU designation number  \\\n",
       "1     Prevention of post-transplantation lympho-prol...           EU/3/02/118   \n",
       "3             Treatment of non-ketotic hyperglycinaemia           EU/3/02/111   \n",
       "5                 Treatment of hepatocellular carcinoma           EU/3/02/110   \n",
       "8     Treatment of partial deep dermal and full-thic...           EU/3/02/107   \n",
       "10    Adjunctive treatment in patients at risk of me...           EU/3/02/128   \n",
       "...                                                 ...                   ...   \n",
       "1663             Treatment of Becker muscular dystrophy          EU/3/20/2293   \n",
       "1664         Treatment of idiopathic pulmonary fibrosis          EU/3/20/2294   \n",
       "1665                            Diagnosis of insulinoma          EU/3/20/2295   \n",
       "1666                Treatment of marginal zone lymphoma          EU/3/20/2296   \n",
       "1667          treatment of metachromatic leukodystrophy          EU/3/20/2297   \n",
       "\n",
       "     Status of orphan designation     First published       Revision date  \\\n",
       "1                        Positive 2002-12-17 01:09:00 2002-12-17 01:09:00   \n",
       "3                        Positive 2003-01-08 01:09:00 2003-01-08 01:09:00   \n",
       "5                        Positive 2003-01-08 01:09:21 2003-01-08 01:09:21   \n",
       "8                        Positive 2003-01-08 02:00:00 2013-09-19 12:00:00   \n",
       "10                       Positive 2003-02-17 02:00:00 2020-04-02 09:20:00   \n",
       "...                           ...                 ...                 ...   \n",
       "1663                     Positive 2020-09-23 15:45:00                 NaT   \n",
       "1664                     Positive 2020-09-23 15:45:00                 NaT   \n",
       "1665                     Positive 2020-09-24 12:32:00                 NaT   \n",
       "1666                     Positive 2020-09-24 14:40:00                 NaT   \n",
       "1667                     Positive 2020-09-24 14:40:00                 NaT   \n",
       "\n",
       "                                                    URL  \\\n",
       "1     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "3     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "5     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "8     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "10    https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "...                                                 ...   \n",
       "1663  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1664  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1665  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1666  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1667  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "\n",
       "                                                Product  \\\n",
       "1     recombinant glycoprotein gp350 of epstein-barr...   \n",
       "3                             benzoic acid, sodium salt   \n",
       "5                                           thymalfasin   \n",
       "8                                    purified bromelain   \n",
       "10                                  carboxypeptidase g2   \n",
       "...                                                 ...   \n",
       "1663                                    (+)-epicatechin   \n",
       "1664                                sodium cromoglicate   \n",
       "1665                    lys40(nodaga-68ga)nh2-exendin-4   \n",
       "1666                            axicabtagene ciloleucel   \n",
       "1667  adeno-associated virus serotype hsc15 expressi...   \n",
       "\n",
       "                                             Indication  \\\n",
       "1     Prevention of post transplantation lympho-prol...   \n",
       "3             Treatment of non-ketotic hyperglycinaemia   \n",
       "5                 Treatment of hepatocellular carcinoma   \n",
       "8     Treatment of partial deep dermal and full thic...   \n",
       "10    Adjunctive treatment in patients at risk of me...   \n",
       "...                                                 ...   \n",
       "1663             Treatment of Becker muscular dystrophy   \n",
       "1664         Treatment of idiopathic pulmonary fibrosis   \n",
       "1665                            Diagnosis of insulinoma   \n",
       "1666                Treatment of marginal zone lymphoma   \n",
       "1667          Treatment of metachromatic leukodystrophy   \n",
       "\n",
       "                                           Sponsor Designation date  \\\n",
       "1                                     Henogen S.A.      22 Oct 2002   \n",
       "3                                    Ethicare GmbH      11 Sep 2002   \n",
       "5             SciClone Pharmaceuticals Italy S.r.l      30 Jul 2002   \n",
       "8                           MediWound Germany GmbH      30 Jul 2002   \n",
       "10    Protherics Medicines Development Europe B.V.      03 Feb 2003   \n",
       "...                                            ...              ...   \n",
       "1663                       MWB Consulting S.A.R.L.      26 Jun 2020   \n",
       "1664                          IQVIA RDS Spain S.L.      26 Jun 2020   \n",
       "1665             Stichting Katholieke Universiteit      26 Jun 2020   \n",
       "1666                           Kite Pharma EU B.V.      26 Jun 2020   \n",
       "1667  Yes Pharmaceutical Development Services GmbH      26 Jun 2020   \n",
       "\n",
       "     Tradename - EU product # - Implemented on  \n",
       "1                                            -  \n",
       "3                                            -  \n",
       "5                                            -  \n",
       "8     NexoBrid - \\nEU/1/12/803 - \\n20 Dec 2012  \n",
       "10                                           -  \n",
       "...                                        ...  \n",
       "1663                                         -  \n",
       "1664                                         -  \n",
       "1665                                         -  \n",
       "1666                                         -  \n",
       "1667                                         -  \n",
       "\n",
       "[1357 rows x 15 columns]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Get active substance column\n",
    "\n",
    "# Make all lower case to simplify matching\n",
    "matched_data['Active substance'] = matched_data['Active substance'].str.lower()\n",
    "matched_data['Product'] = matched_data['Product'].str.lower()\n",
    "\n",
    "product_filtered_data = matched_data[matched_data['Active substance'] == matched_data['Product']]\n",
    "product_filtered_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Get entries where 'Product' and 'Active substance' do not match"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Medicine name</th>\n",
       "      <th>Active substance</th>\n",
       "      <th>Agency product number</th>\n",
       "      <th>Date of first decision</th>\n",
       "      <th>Disease / condition</th>\n",
       "      <th>EU designation number</th>\n",
       "      <th>Status of orphan designation</th>\n",
       "      <th>First published</th>\n",
       "      <th>Revision date</th>\n",
       "      <th>URL</th>\n",
       "      <th>Product</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Sponsor</th>\n",
       "      <th>Designation date</th>\n",
       "      <th>Tradename - EU product # - Implemented on</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NaN</td>\n",
       "      <td>etilefrine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2002-11-13 01:00:00</td>\n",
       "      <td>Treatment of low-flow priapism</td>\n",
       "      <td>EU/3/02/122</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2002-12-13 01:09:21</td>\n",
       "      <td>2013-06-25 16:15:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>etilefrin</td>\n",
       "      <td>Treatment of low flow priapism</td>\n",
       "      <td>Laboratoires SERB</td>\n",
       "      <td>13 Nov 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Cerepro,</td>\n",
       "      <td>adenovirus-mediated herpes-simplex-virus thymi...</td>\n",
       "      <td>EMEA/H/C/000694</td>\n",
       "      <td>2002-02-06 01:00:00</td>\n",
       "      <td>Treatment of high-grade glioma with subsequent...</td>\n",
       "      <td>EU/3/01/083</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2003-01-06 02:00:00</td>\n",
       "      <td>2016-08-15 18:40:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>adenovirus-mediated herpes simplex virus-thymi...</td>\n",
       "      <td>Treatment of high-grade glioma with subsequent...</td>\n",
       "      <td>Boyd Consultants Limited</td>\n",
       "      <td>06 Feb 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NaN</td>\n",
       "      <td>autologous renal cell tumour vaccine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2002-10-21 00:00:00</td>\n",
       "      <td>Treatment of renal-cell carcinoma</td>\n",
       "      <td>EU/3/02/116</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2003-01-08 01:09:00</td>\n",
       "      <td>2003-01-08 01:09:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>autologous renal cell tumor vaccine</td>\n",
       "      <td>Treatment of renal cell carcinoma</td>\n",
       "      <td>Liponova GmbH</td>\n",
       "      <td>21 Oct 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NaN</td>\n",
       "      <td>tgf-ß2-specific phosphorothioate antisense oli...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2002-03-22 02:00:00</td>\n",
       "      <td>Treatment of high-grade glioma</td>\n",
       "      <td>EU/3/02/091</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2003-01-08 02:00:00</td>\n",
       "      <td>2014-04-03 16:11:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>tgf-beta2 specific phosphorothioate antisense ...</td>\n",
       "      <td>Treatment of high-grade glioma</td>\n",
       "      <td>Dr Ulrich Granzer</td>\n",
       "      <td>22 Mar 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NaN</td>\n",
       "      <td>chimeric igg monoclonal antibody cg250 (girent...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2002-03-19 01:00:00</td>\n",
       "      <td>Treatment of renal-cell carcinoma</td>\n",
       "      <td>EU/3/02/094</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2003-01-08 02:00:00</td>\n",
       "      <td>2017-11-22 18:50:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>chimeric igg monoclonal antibody cg250</td>\n",
       "      <td>Treatment of renal cell carcinoma</td>\n",
       "      <td>Heidelberg Pharma AG</td>\n",
       "      <td>19 Mar 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1564</th>\n",
       "      <td>NaN</td>\n",
       "      <td>sodium benzoate</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2019-06-28 00:00:00</td>\n",
       "      <td>Treatment of argininosuccinic aciduria</td>\n",
       "      <td>EU/3/19/2178</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2019-10-14 15:25:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>sodium benzoate, sodium phenylacetate</td>\n",
       "      <td>Treatment of argininosuccinic aciduria</td>\n",
       "      <td>Dipharma B.V.</td>\n",
       "      <td>28 Jun 2019</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1565</th>\n",
       "      <td>NaN</td>\n",
       "      <td>sodium benzoate</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2019-06-28 00:00:00</td>\n",
       "      <td>Treatment of hyperargininaemia</td>\n",
       "      <td>EU/3/19/2179</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2019-10-14 15:40:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>sodium benzoate, sodium phenylacetate</td>\n",
       "      <td>Treatment of hyperargininaemia</td>\n",
       "      <td>Dipharma B.V.</td>\n",
       "      <td>28 Jun 2019</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1592</th>\n",
       "      <td>NaN</td>\n",
       "      <td>autologous peripheral blood t cells cd4 and cd...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2019-11-13 01:00:00</td>\n",
       "      <td>Treatment of mantle cell lymphoma</td>\n",
       "      <td>EU/3/19/2220</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-02-13 09:56:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>autologous peripheral blood t cells cd4 and cd...</td>\n",
       "      <td>Treatment of mantle cell lymphoma</td>\n",
       "      <td>Kite Pharma EU B.V.</td>\n",
       "      <td>13 Nov 2019</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1616</th>\n",
       "      <td>NaN</td>\n",
       "      <td>combination of three adeno-associated viral ve...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-02-28 01:00:00</td>\n",
       "      <td>Treatment of inherited retinal dystrophies</td>\n",
       "      <td>EU/3/20/2254</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-05-06 11:30:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>combination of three adeno-associated viral ve...</td>\n",
       "      <td>Treatment of inherited retinal dystrophies</td>\n",
       "      <td>Fondazione Telethon</td>\n",
       "      <td>28 Feb 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1634</th>\n",
       "      <td>NaN</td>\n",
       "      <td>allogeneic multi-virus specific t lymphocytes ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-03-24 01:00:00</td>\n",
       "      <td>Treatment in haematopoietic stem cell transpla...</td>\n",
       "      <td>EU/3/20/2260</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-08-12 10:45:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>allogeneic multi-virus specific t lymphocytes ...</td>\n",
       "      <td>Treatment in haematopoietic stem cell transpla...</td>\n",
       "      <td>TMC Pharma (EU) Limited</td>\n",
       "      <td>24 Mar 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>311 rows × 15 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Medicine name                                   Active substance  \\\n",
       "0              NaN                                         etilefrine   \n",
       "2        Cerepro,   adenovirus-mediated herpes-simplex-virus thymi...   \n",
       "4              NaN               autologous renal cell tumour vaccine   \n",
       "6              NaN  tgf-ß2-specific phosphorothioate antisense oli...   \n",
       "7              NaN  chimeric igg monoclonal antibody cg250 (girent...   \n",
       "...            ...                                                ...   \n",
       "1564           NaN                                    sodium benzoate   \n",
       "1565           NaN                                    sodium benzoate   \n",
       "1592           NaN  autologous peripheral blood t cells cd4 and cd...   \n",
       "1616           NaN  combination of three adeno-associated viral ve...   \n",
       "1634           NaN  allogeneic multi-virus specific t lymphocytes ...   \n",
       "\n",
       "     Agency product number Date of first decision  \\\n",
       "0                      NaN    2002-11-13 01:00:00   \n",
       "2          EMEA/H/C/000694    2002-02-06 01:00:00   \n",
       "4                      NaN    2002-10-21 00:00:00   \n",
       "6                      NaN    2002-03-22 02:00:00   \n",
       "7                      NaN    2002-03-19 01:00:00   \n",
       "...                    ...                    ...   \n",
       "1564                   NaN    2019-06-28 00:00:00   \n",
       "1565                   NaN    2019-06-28 00:00:00   \n",
       "1592                   NaN    2019-11-13 01:00:00   \n",
       "1616                   NaN    2020-02-28 01:00:00   \n",
       "1634                   NaN    2020-03-24 01:00:00   \n",
       "\n",
       "                                    Disease / condition EU designation number  \\\n",
       "0                        Treatment of low-flow priapism           EU/3/02/122   \n",
       "2     Treatment of high-grade glioma with subsequent...           EU/3/01/083   \n",
       "4                     Treatment of renal-cell carcinoma           EU/3/02/116   \n",
       "6                        Treatment of high-grade glioma           EU/3/02/091   \n",
       "7                     Treatment of renal-cell carcinoma           EU/3/02/094   \n",
       "...                                                 ...                   ...   \n",
       "1564             Treatment of argininosuccinic aciduria          EU/3/19/2178   \n",
       "1565                     Treatment of hyperargininaemia          EU/3/19/2179   \n",
       "1592                  Treatment of mantle cell lymphoma          EU/3/19/2220   \n",
       "1616         Treatment of inherited retinal dystrophies          EU/3/20/2254   \n",
       "1634  Treatment in haematopoietic stem cell transpla...          EU/3/20/2260   \n",
       "\n",
       "     Status of orphan designation     First published       Revision date  \\\n",
       "0                        Positive 2002-12-13 01:09:21 2013-06-25 16:15:00   \n",
       "2                        Positive 2003-01-06 02:00:00 2016-08-15 18:40:00   \n",
       "4                        Positive 2003-01-08 01:09:00 2003-01-08 01:09:00   \n",
       "6                        Positive 2003-01-08 02:00:00 2014-04-03 16:11:00   \n",
       "7                        Positive 2003-01-08 02:00:00 2017-11-22 18:50:00   \n",
       "...                           ...                 ...                 ...   \n",
       "1564                     Positive 2019-10-14 15:25:00                 NaT   \n",
       "1565                     Positive 2019-10-14 15:40:00                 NaT   \n",
       "1592                     Positive 2020-02-13 09:56:00                 NaT   \n",
       "1616                     Positive 2020-05-06 11:30:00                 NaT   \n",
       "1634                     Positive 2020-08-12 10:45:00                 NaT   \n",
       "\n",
       "                                                    URL  \\\n",
       "0     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "2     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "4     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "6     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "7     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "...                                                 ...   \n",
       "1564  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1565  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1592  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1616  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1634  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "\n",
       "                                                Product  \\\n",
       "0                                             etilefrin   \n",
       "2     adenovirus-mediated herpes simplex virus-thymi...   \n",
       "4                   autologous renal cell tumor vaccine   \n",
       "6     tgf-beta2 specific phosphorothioate antisense ...   \n",
       "7                chimeric igg monoclonal antibody cg250   \n",
       "...                                                 ...   \n",
       "1564              sodium benzoate, sodium phenylacetate   \n",
       "1565              sodium benzoate, sodium phenylacetate   \n",
       "1592  autologous peripheral blood t cells cd4 and cd...   \n",
       "1616  combination of three adeno-associated viral ve...   \n",
       "1634  allogeneic multi-virus specific t lymphocytes ...   \n",
       "\n",
       "                                             Indication  \\\n",
       "0                        Treatment of low flow priapism   \n",
       "2     Treatment of high-grade glioma with subsequent...   \n",
       "4                     Treatment of renal cell carcinoma   \n",
       "6                        Treatment of high-grade glioma   \n",
       "7                     Treatment of renal cell carcinoma   \n",
       "...                                                 ...   \n",
       "1564             Treatment of argininosuccinic aciduria   \n",
       "1565                     Treatment of hyperargininaemia   \n",
       "1592                  Treatment of mantle cell lymphoma   \n",
       "1616         Treatment of inherited retinal dystrophies   \n",
       "1634  Treatment in haematopoietic stem cell transpla...   \n",
       "\n",
       "                       Sponsor Designation date  \\\n",
       "0            Laboratoires SERB      13 Nov 2002   \n",
       "2     Boyd Consultants Limited      06 Feb 2002   \n",
       "4                Liponova GmbH      21 Oct 2002   \n",
       "6            Dr Ulrich Granzer      22 Mar 2002   \n",
       "7         Heidelberg Pharma AG      19 Mar 2002   \n",
       "...                        ...              ...   \n",
       "1564             Dipharma B.V.      28 Jun 2019   \n",
       "1565             Dipharma B.V.      28 Jun 2019   \n",
       "1592       Kite Pharma EU B.V.      13 Nov 2019   \n",
       "1616       Fondazione Telethon      28 Feb 2020   \n",
       "1634   TMC Pharma (EU) Limited      24 Mar 2020   \n",
       "\n",
       "     Tradename - EU product # - Implemented on  \n",
       "0                                            -  \n",
       "2                                            -  \n",
       "4                                            -  \n",
       "6                                            -  \n",
       "7                                            -  \n",
       "...                                        ...  \n",
       "1564                                         -  \n",
       "1565                                         -  \n",
       "1592                                         -  \n",
       "1616                                         -  \n",
       "1634                                         -  \n",
       "\n",
       "[311 rows x 15 columns]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Get active substance column\n",
    "product_filtered_data = matched_data[matched_data['Active substance'] != matched_data['Product']]\n",
    "product_filtered_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "They seem to be identical! Differnences are probably just documentation discrepancies."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Medicine name</th>\n",
       "      <th>Active substance</th>\n",
       "      <th>Agency product number</th>\n",
       "      <th>Date of first decision</th>\n",
       "      <th>Disease / condition</th>\n",
       "      <th>EU designation number</th>\n",
       "      <th>Status of orphan designation</th>\n",
       "      <th>First published</th>\n",
       "      <th>Revision date</th>\n",
       "      <th>URL</th>\n",
       "      <th>Product</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Sponsor</th>\n",
       "      <th>Designation date</th>\n",
       "      <th>Tradename - EU product # - Implemented on</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NaN</td>\n",
       "      <td>etilefrine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2002-11-13 01:00:00</td>\n",
       "      <td>Treatment of low-flow priapism</td>\n",
       "      <td>EU/3/02/122</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2002-12-13 01:09:21</td>\n",
       "      <td>2013-06-25 16:15:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>etilefrin</td>\n",
       "      <td>Treatment of low flow priapism</td>\n",
       "      <td>Laboratoires SERB</td>\n",
       "      <td>13 Nov 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NaN</td>\n",
       "      <td>recombinant glycoprotein gp350 of epstein-barr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2002-10-22 00:00:00</td>\n",
       "      <td>Prevention of post-transplantation lympho-prol...</td>\n",
       "      <td>EU/3/02/118</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2002-12-17 01:09:00</td>\n",
       "      <td>2002-12-17 01:09:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>recombinant glycoprotein gp350 of epstein-barr...</td>\n",
       "      <td>Prevention of post transplantation lympho-prol...</td>\n",
       "      <td>Henogen S.A.</td>\n",
       "      <td>22 Oct 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Cerepro,</td>\n",
       "      <td>adenovirus-mediated herpes-simplex-virus thymi...</td>\n",
       "      <td>EMEA/H/C/000694</td>\n",
       "      <td>2002-02-06 01:00:00</td>\n",
       "      <td>Treatment of high-grade glioma with subsequent...</td>\n",
       "      <td>EU/3/01/083</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2003-01-06 02:00:00</td>\n",
       "      <td>2016-08-15 18:40:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>adenovirus-mediated herpes simplex virus-thymi...</td>\n",
       "      <td>Treatment of high-grade glioma with subsequent...</td>\n",
       "      <td>Boyd Consultants Limited</td>\n",
       "      <td>06 Feb 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Prohippur,</td>\n",
       "      <td>benzoic acid, sodium salt</td>\n",
       "      <td>EMEA/H/C/004150</td>\n",
       "      <td>2002-09-11 00:00:00</td>\n",
       "      <td>Treatment of non-ketotic hyperglycinaemia</td>\n",
       "      <td>EU/3/02/111</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2003-01-08 01:09:00</td>\n",
       "      <td>2003-01-08 01:09:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>benzoic acid, sodium salt</td>\n",
       "      <td>Treatment of non-ketotic hyperglycinaemia</td>\n",
       "      <td>Ethicare GmbH</td>\n",
       "      <td>11 Sep 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NaN</td>\n",
       "      <td>autologous renal cell tumour vaccine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2002-10-21 00:00:00</td>\n",
       "      <td>Treatment of renal-cell carcinoma</td>\n",
       "      <td>EU/3/02/116</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2003-01-08 01:09:00</td>\n",
       "      <td>2003-01-08 01:09:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>autologous renal cell tumor vaccine</td>\n",
       "      <td>Treatment of renal cell carcinoma</td>\n",
       "      <td>Liponova GmbH</td>\n",
       "      <td>21 Oct 2002</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1663</th>\n",
       "      <td>NaN</td>\n",
       "      <td>(+)-epicatechin</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>Treatment of Becker muscular dystrophy</td>\n",
       "      <td>EU/3/20/2293</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-23 15:45:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>(+)-epicatechin</td>\n",
       "      <td>Treatment of Becker muscular dystrophy</td>\n",
       "      <td>MWB Consulting S.A.R.L.</td>\n",
       "      <td>26 Jun 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1664</th>\n",
       "      <td>NaN</td>\n",
       "      <td>sodium cromoglicate</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>Treatment of idiopathic pulmonary fibrosis</td>\n",
       "      <td>EU/3/20/2294</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-23 15:45:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>sodium cromoglicate</td>\n",
       "      <td>Treatment of idiopathic pulmonary fibrosis</td>\n",
       "      <td>IQVIA RDS Spain S.L.</td>\n",
       "      <td>26 Jun 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1665</th>\n",
       "      <td>NaN</td>\n",
       "      <td>lys40(nodaga-68ga)nh2-exendin-4</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>Diagnosis of insulinoma</td>\n",
       "      <td>EU/3/20/2295</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-24 12:32:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>lys40(nodaga-68ga)nh2-exendin-4</td>\n",
       "      <td>Diagnosis of insulinoma</td>\n",
       "      <td>Stichting Katholieke Universiteit</td>\n",
       "      <td>26 Jun 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1666</th>\n",
       "      <td>NaN</td>\n",
       "      <td>axicabtagene ciloleucel</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>Treatment of marginal zone lymphoma</td>\n",
       "      <td>EU/3/20/2296</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-24 14:40:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>axicabtagene ciloleucel</td>\n",
       "      <td>Treatment of marginal zone lymphoma</td>\n",
       "      <td>Kite Pharma EU B.V.</td>\n",
       "      <td>26 Jun 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1667</th>\n",
       "      <td>NaN</td>\n",
       "      <td>adeno-associated virus serotype hsc15 expressi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-06-26 00:00:00</td>\n",
       "      <td>treatment of metachromatic leukodystrophy</td>\n",
       "      <td>EU/3/20/2297</td>\n",
       "      <td>Positive</td>\n",
       "      <td>2020-09-24 14:40:00</td>\n",
       "      <td>NaT</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "      <td>adeno-associated virus serotype hsc15 expressi...</td>\n",
       "      <td>Treatment of metachromatic leukodystrophy</td>\n",
       "      <td>Yes Pharmaceutical Development Services GmbH</td>\n",
       "      <td>26 Jun 2020</td>\n",
       "      <td>-</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1668 rows × 15 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Medicine name                                   Active substance  \\\n",
       "0              NaN                                         etilefrine   \n",
       "1              NaN  recombinant glycoprotein gp350 of epstein-barr...   \n",
       "2        Cerepro,   adenovirus-mediated herpes-simplex-virus thymi...   \n",
       "3      Prohippur,                           benzoic acid, sodium salt   \n",
       "4              NaN               autologous renal cell tumour vaccine   \n",
       "...            ...                                                ...   \n",
       "1663           NaN                                    (+)-epicatechin   \n",
       "1664           NaN                                sodium cromoglicate   \n",
       "1665           NaN                    lys40(nodaga-68ga)nh2-exendin-4   \n",
       "1666           NaN                            axicabtagene ciloleucel   \n",
       "1667           NaN  adeno-associated virus serotype hsc15 expressi...   \n",
       "\n",
       "     Agency product number Date of first decision  \\\n",
       "0                      NaN    2002-11-13 01:00:00   \n",
       "1                      NaN    2002-10-22 00:00:00   \n",
       "2          EMEA/H/C/000694    2002-02-06 01:00:00   \n",
       "3          EMEA/H/C/004150    2002-09-11 00:00:00   \n",
       "4                      NaN    2002-10-21 00:00:00   \n",
       "...                    ...                    ...   \n",
       "1663                   NaN    2020-06-26 00:00:00   \n",
       "1664                   NaN    2020-06-26 00:00:00   \n",
       "1665                   NaN    2020-06-26 00:00:00   \n",
       "1666                   NaN    2020-06-26 00:00:00   \n",
       "1667                   NaN    2020-06-26 00:00:00   \n",
       "\n",
       "                                    Disease / condition EU designation number  \\\n",
       "0                        Treatment of low-flow priapism           EU/3/02/122   \n",
       "1     Prevention of post-transplantation lympho-prol...           EU/3/02/118   \n",
       "2     Treatment of high-grade glioma with subsequent...           EU/3/01/083   \n",
       "3             Treatment of non-ketotic hyperglycinaemia           EU/3/02/111   \n",
       "4                     Treatment of renal-cell carcinoma           EU/3/02/116   \n",
       "...                                                 ...                   ...   \n",
       "1663             Treatment of Becker muscular dystrophy          EU/3/20/2293   \n",
       "1664         Treatment of idiopathic pulmonary fibrosis          EU/3/20/2294   \n",
       "1665                            Diagnosis of insulinoma          EU/3/20/2295   \n",
       "1666                Treatment of marginal zone lymphoma          EU/3/20/2296   \n",
       "1667          treatment of metachromatic leukodystrophy          EU/3/20/2297   \n",
       "\n",
       "     Status of orphan designation     First published       Revision date  \\\n",
       "0                        Positive 2002-12-13 01:09:21 2013-06-25 16:15:00   \n",
       "1                        Positive 2002-12-17 01:09:00 2002-12-17 01:09:00   \n",
       "2                        Positive 2003-01-06 02:00:00 2016-08-15 18:40:00   \n",
       "3                        Positive 2003-01-08 01:09:00 2003-01-08 01:09:00   \n",
       "4                        Positive 2003-01-08 01:09:00 2003-01-08 01:09:00   \n",
       "...                           ...                 ...                 ...   \n",
       "1663                     Positive 2020-09-23 15:45:00                 NaT   \n",
       "1664                     Positive 2020-09-23 15:45:00                 NaT   \n",
       "1665                     Positive 2020-09-24 12:32:00                 NaT   \n",
       "1666                     Positive 2020-09-24 14:40:00                 NaT   \n",
       "1667                     Positive 2020-09-24 14:40:00                 NaT   \n",
       "\n",
       "                                                    URL  \\\n",
       "0     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "2     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "3     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "4     https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "...                                                 ...   \n",
       "1663  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1664  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1665  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1666  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "1667  https://www.ema.europa.eu/en/medicines/human/o...   \n",
       "\n",
       "                                                Product  \\\n",
       "0                                             etilefrin   \n",
       "1     recombinant glycoprotein gp350 of epstein-barr...   \n",
       "2     adenovirus-mediated herpes simplex virus-thymi...   \n",
       "3                             benzoic acid, sodium salt   \n",
       "4                   autologous renal cell tumor vaccine   \n",
       "...                                                 ...   \n",
       "1663                                    (+)-epicatechin   \n",
       "1664                                sodium cromoglicate   \n",
       "1665                    lys40(nodaga-68ga)nh2-exendin-4   \n",
       "1666                            axicabtagene ciloleucel   \n",
       "1667  adeno-associated virus serotype hsc15 expressi...   \n",
       "\n",
       "                                             Indication  \\\n",
       "0                        Treatment of low flow priapism   \n",
       "1     Prevention of post transplantation lympho-prol...   \n",
       "2     Treatment of high-grade glioma with subsequent...   \n",
       "3             Treatment of non-ketotic hyperglycinaemia   \n",
       "4                     Treatment of renal cell carcinoma   \n",
       "...                                                 ...   \n",
       "1663             Treatment of Becker muscular dystrophy   \n",
       "1664         Treatment of idiopathic pulmonary fibrosis   \n",
       "1665                            Diagnosis of insulinoma   \n",
       "1666                Treatment of marginal zone lymphoma   \n",
       "1667          Treatment of metachromatic leukodystrophy   \n",
       "\n",
       "                                           Sponsor Designation date  \\\n",
       "0                                Laboratoires SERB      13 Nov 2002   \n",
       "1                                     Henogen S.A.      22 Oct 2002   \n",
       "2                         Boyd Consultants Limited      06 Feb 2002   \n",
       "3                                    Ethicare GmbH      11 Sep 2002   \n",
       "4                                    Liponova GmbH      21 Oct 2002   \n",
       "...                                            ...              ...   \n",
       "1663                       MWB Consulting S.A.R.L.      26 Jun 2020   \n",
       "1664                          IQVIA RDS Spain S.L.      26 Jun 2020   \n",
       "1665             Stichting Katholieke Universiteit      26 Jun 2020   \n",
       "1666                           Kite Pharma EU B.V.      26 Jun 2020   \n",
       "1667  Yes Pharmaceutical Development Services GmbH      26 Jun 2020   \n",
       "\n",
       "     Tradename - EU product # - Implemented on  \n",
       "0                                            -  \n",
       "1                                            -  \n",
       "2                                            -  \n",
       "3                                            -  \n",
       "4                                            -  \n",
       "...                                        ...  \n",
       "1663                                         -  \n",
       "1664                                         -  \n",
       "1665                                         -  \n",
       "1666                                         -  \n",
       "1667                                         -  \n",
       "\n",
       "[1668 rows x 15 columns]"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matched_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Import dataset of all drugs from https://www.ema.europa.eu/en/medicines/download-medicine-data (EPAR)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['Veterinary' 'Human']\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Category</th>\n",
       "      <th>Medicine name</th>\n",
       "      <th>Therapeutic area</th>\n",
       "      <th>International non-proprietary name (INN) / common name</th>\n",
       "      <th>Active substance</th>\n",
       "      <th>Product number</th>\n",
       "      <th>Patient safety</th>\n",
       "      <th>Authorisation status</th>\n",
       "      <th>ATC code</th>\n",
       "      <th>Additional monitoring</th>\n",
       "      <th>...</th>\n",
       "      <th>Vet pharmacotherapeutic group</th>\n",
       "      <th>Date of opinion</th>\n",
       "      <th>Decision date</th>\n",
       "      <th>Revision number</th>\n",
       "      <th>Condition / indication</th>\n",
       "      <th>Species</th>\n",
       "      <th>ATCvet code</th>\n",
       "      <th>First published</th>\n",
       "      <th>Revision date</th>\n",
       "      <th>URL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Veterinary</td>\n",
       "      <td>Frontpro (previously known as Afoxolaner Merial)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>afoxolaner</td>\n",
       "      <td>afoxolaner</td>\n",
       "      <td>EMEA/V/C/005126</td>\n",
       "      <td>no</td>\n",
       "      <td>Authorised</td>\n",
       "      <td>NaN</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>Ectoparasiticides for systemic use</td>\n",
       "      <td>2019-03-21 01:00:00</td>\n",
       "      <td>2020-11-06 01:00:00</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Treatment of flea (Ctenocephalides felis and C...</td>\n",
       "      <td>Dogs</td>\n",
       "      <td>QP53BE01</td>\n",
       "      <td>2019-06-07 17:00:00</td>\n",
       "      <td>2020-11-12 18:18:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/veterin...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Human</td>\n",
       "      <td>Cholib</td>\n",
       "      <td>Dyslipidemias</td>\n",
       "      <td>fenofibrate, simvastatin</td>\n",
       "      <td>fenofibrate, simvastatin</td>\n",
       "      <td>EMEA/H/C/002559</td>\n",
       "      <td>no</td>\n",
       "      <td>Authorised</td>\n",
       "      <td>C10BA04</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2013-06-27 00:00:00</td>\n",
       "      <td>2020-10-23 00:00:00</td>\n",
       "      <td>12.0</td>\n",
       "      <td>Cholib is indicated as adjunctive therapy to d...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2018-08-20 00:00:00</td>\n",
       "      <td>2020-11-12 17:50:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Human</td>\n",
       "      <td>Repaglinide Krka</td>\n",
       "      <td>Diabetes Mellitus, Type 2</td>\n",
       "      <td>repaglinide</td>\n",
       "      <td>repaglinide</td>\n",
       "      <td>EMEA/H/C/001066</td>\n",
       "      <td>no</td>\n",
       "      <td>Authorised</td>\n",
       "      <td>A10BX02</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2009-07-23 00:00:00</td>\n",
       "      <td>2020-10-28 01:00:00</td>\n",
       "      <td>6.0</td>\n",
       "      <td>Repaglinide is indicated in patients with type...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-10-27 00:00:00</td>\n",
       "      <td>2020-11-12 17:30:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Human</td>\n",
       "      <td>Liprolog</td>\n",
       "      <td>Diabetes Mellitus</td>\n",
       "      <td>insulin lispro</td>\n",
       "      <td>insulin lispro</td>\n",
       "      <td>EMEA/H/C/000393</td>\n",
       "      <td>no</td>\n",
       "      <td>Authorised</td>\n",
       "      <td>A10AB04, A10AD04</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2001-04-26 00:00:00</td>\n",
       "      <td>2020-09-04 00:00:00</td>\n",
       "      <td>28.0</td>\n",
       "      <td>For the treatment of adults and children with ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-10-23 00:00:00</td>\n",
       "      <td>2020-11-12 16:54:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Human</td>\n",
       "      <td>Hexacima</td>\n",
       "      <td>Hepatitis B, Tetanus, Immunization, Meningitis...</td>\n",
       "      <td>diphtheria, tetanus, pertussis (acellular, com...</td>\n",
       "      <td>diphtheria toxoid / tetanus toxoid, two-compon...</td>\n",
       "      <td>EMEA/H/C/002702</td>\n",
       "      <td>no</td>\n",
       "      <td>Authorised</td>\n",
       "      <td>J07CA09</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2013-02-21 01:00:00</td>\n",
       "      <td>2020-09-24 00:00:00</td>\n",
       "      <td>21.0</td>\n",
       "      <td>Hexacima (DTaP-IPV-HB-Hib) is indicated for pr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2018-01-08 12:30:00</td>\n",
       "      <td>2020-11-12 16:42:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1730</th>\n",
       "      <td>Human</td>\n",
       "      <td>Liprolog</td>\n",
       "      <td>Diabetes Mellitus</td>\n",
       "      <td>insulin lispro</td>\n",
       "      <td>insulin lispro</td>\n",
       "      <td>EMEA/H/C/000143</td>\n",
       "      <td>no</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>A10AB04</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2001-02-19 01:00:00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>For the treatment of patients with diabetes me...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2001-02-19 01:00:00</td>\n",
       "      <td>2001-08-01 00:00:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1731</th>\n",
       "      <td>Human</td>\n",
       "      <td>EchoGen</td>\n",
       "      <td>Echocardiography</td>\n",
       "      <td>dodecafluoropentane</td>\n",
       "      <td>dodecafluoropentane</td>\n",
       "      <td>EMEA/H/C/000149</td>\n",
       "      <td>no</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>V08DA</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2001-01-22 01:00:00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>EchoGen is a transpulmonary echocardiographic ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2001-01-22 01:00:00</td>\n",
       "      <td>2001-05-22 00:00:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1732</th>\n",
       "      <td>Human</td>\n",
       "      <td>Ecokinase</td>\n",
       "      <td>Myocardial Infarction</td>\n",
       "      <td>reteplase</td>\n",
       "      <td>reteplase</td>\n",
       "      <td>EMEA/H/C/000106</td>\n",
       "      <td>no</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>B01AD07</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaT</td>\n",
       "      <td>1999-07-30 00:00:00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>Thrombolytic therapy of acute myocardial infar...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1999-07-30 00:00:00</td>\n",
       "      <td>2000-12-12 01:00:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1733</th>\n",
       "      <td>Human</td>\n",
       "      <td>Primavax</td>\n",
       "      <td>Hepatitis B, Tetanus, Immunization, Diphtheria</td>\n",
       "      <td>diphtheria, tetanus and hepatitis B vaccine, a...</td>\n",
       "      <td>diphtheria toxoid purified, hepatitis B, recom...</td>\n",
       "      <td>EMEA/H/C/000156</td>\n",
       "      <td>no</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>J07CA</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2000-07-27 00:00:00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>This vaccine is indicated for active immunizat...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2000-07-27 00:00:00</td>\n",
       "      <td>2000-12-04 01:00:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1734</th>\n",
       "      <td>Human</td>\n",
       "      <td>Pylori-Chek</td>\n",
       "      <td>Breath Tests, Helicobacter Infections</td>\n",
       "      <td>13C-urea</td>\n",
       "      <td>13C-urea</td>\n",
       "      <td>EMEA/H/C/000182</td>\n",
       "      <td>no</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>V04CX</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2000-07-05 02:00:00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>Pylori-Chek may be used for in vivo diagnosis ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2000-07-05 02:00:00</td>\n",
       "      <td>2000-07-17 02:00:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1735 rows × 30 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        Category                                     Medicine name  \\\n",
       "0     Veterinary  Frontpro (previously known as Afoxolaner Merial)   \n",
       "1          Human                                            Cholib   \n",
       "2          Human                                  Repaglinide Krka   \n",
       "3          Human                                          Liprolog   \n",
       "4          Human                                          Hexacima   \n",
       "...          ...                                               ...   \n",
       "1730       Human                                          Liprolog   \n",
       "1731       Human                                           EchoGen   \n",
       "1732       Human                                         Ecokinase   \n",
       "1733       Human                                          Primavax   \n",
       "1734       Human                                       Pylori-Chek   \n",
       "\n",
       "                                       Therapeutic area  \\\n",
       "0                                                   NaN   \n",
       "1                                         Dyslipidemias   \n",
       "2                             Diabetes Mellitus, Type 2   \n",
       "3                                     Diabetes Mellitus   \n",
       "4     Hepatitis B, Tetanus, Immunization, Meningitis...   \n",
       "...                                                 ...   \n",
       "1730                                  Diabetes Mellitus   \n",
       "1731                                   Echocardiography   \n",
       "1732                              Myocardial Infarction   \n",
       "1733     Hepatitis B, Tetanus, Immunization, Diphtheria   \n",
       "1734              Breath Tests, Helicobacter Infections   \n",
       "\n",
       "     International non-proprietary name (INN) / common name  \\\n",
       "0                                            afoxolaner       \n",
       "1                              fenofibrate, simvastatin       \n",
       "2                                           repaglinide       \n",
       "3                                        insulin lispro       \n",
       "4     diphtheria, tetanus, pertussis (acellular, com...       \n",
       "...                                                 ...       \n",
       "1730                                     insulin lispro       \n",
       "1731                                dodecafluoropentane       \n",
       "1732                                          reteplase       \n",
       "1733  diphtheria, tetanus and hepatitis B vaccine, a...       \n",
       "1734                                           13C-urea       \n",
       "\n",
       "                                       Active substance   Product number  \\\n",
       "0                                            afoxolaner  EMEA/V/C/005126   \n",
       "1                              fenofibrate, simvastatin  EMEA/H/C/002559   \n",
       "2                                           repaglinide  EMEA/H/C/001066   \n",
       "3                                        insulin lispro  EMEA/H/C/000393   \n",
       "4     diphtheria toxoid / tetanus toxoid, two-compon...  EMEA/H/C/002702   \n",
       "...                                                 ...              ...   \n",
       "1730                                     insulin lispro  EMEA/H/C/000143   \n",
       "1731                                dodecafluoropentane  EMEA/H/C/000149   \n",
       "1732                                          reteplase  EMEA/H/C/000106   \n",
       "1733  diphtheria toxoid purified, hepatitis B, recom...  EMEA/H/C/000156   \n",
       "1734                                           13C-urea  EMEA/H/C/000182   \n",
       "\n",
       "     Patient safety Authorisation status          ATC code  \\\n",
       "0                no           Authorised               NaN   \n",
       "1                no           Authorised           C10BA04   \n",
       "2                no           Authorised           A10BX02   \n",
       "3                no           Authorised  A10AB04, A10AD04   \n",
       "4                no           Authorised           J07CA09   \n",
       "...             ...                  ...               ...   \n",
       "1730             no            Withdrawn           A10AB04   \n",
       "1731             no            Withdrawn             V08DA   \n",
       "1732             no            Withdrawn           B01AD07   \n",
       "1733             no            Withdrawn             J07CA   \n",
       "1734             no            Withdrawn             V04CX   \n",
       "\n",
       "     Additional monitoring  ...       Vet pharmacotherapeutic group  \\\n",
       "0                       no  ...  Ectoparasiticides for systemic use   \n",
       "1                       no  ...                                 NaN   \n",
       "2                       no  ...                                 NaN   \n",
       "3                       no  ...                                 NaN   \n",
       "4                       no  ...                                 NaN   \n",
       "...                    ...  ...                                 ...   \n",
       "1730                    no  ...                                 NaN   \n",
       "1731                    no  ...                                 NaN   \n",
       "1732                    no  ...                                 NaN   \n",
       "1733                    no  ...                                 NaN   \n",
       "1734                    no  ...                                 NaN   \n",
       "\n",
       "         Date of opinion       Decision date Revision number  \\\n",
       "0    2019-03-21 01:00:00 2020-11-06 01:00:00             3.0   \n",
       "1    2013-06-27 00:00:00 2020-10-23 00:00:00            12.0   \n",
       "2    2009-07-23 00:00:00 2020-10-28 01:00:00             6.0   \n",
       "3    2001-04-26 00:00:00 2020-09-04 00:00:00            28.0   \n",
       "4    2013-02-21 01:00:00 2020-09-24 00:00:00            21.0   \n",
       "...                  ...                 ...             ...   \n",
       "1730                 NaT 2001-02-19 01:00:00             0.0   \n",
       "1731                 NaT 2001-01-22 01:00:00             0.0   \n",
       "1732                 NaT 1999-07-30 00:00:00             0.0   \n",
       "1733                 NaT 2000-07-27 00:00:00             0.0   \n",
       "1734                 NaT 2000-07-05 02:00:00             0.0   \n",
       "\n",
       "                                 Condition / indication Species ATCvet code  \\\n",
       "0     Treatment of flea (Ctenocephalides felis and C...    Dogs    QP53BE01   \n",
       "1     Cholib is indicated as adjunctive therapy to d...     NaN         NaN   \n",
       "2     Repaglinide is indicated in patients with type...     NaN         NaN   \n",
       "3     For the treatment of adults and children with ...     NaN         NaN   \n",
       "4     Hexacima (DTaP-IPV-HB-Hib) is indicated for pr...     NaN         NaN   \n",
       "...                                                 ...     ...         ...   \n",
       "1730  For the treatment of patients with diabetes me...     NaN         NaN   \n",
       "1731  EchoGen is a transpulmonary echocardiographic ...     NaN         NaN   \n",
       "1732  Thrombolytic therapy of acute myocardial infar...     NaN         NaN   \n",
       "1733  This vaccine is indicated for active immunizat...     NaN         NaN   \n",
       "1734  Pylori-Chek may be used for in vivo diagnosis ...     NaN         NaN   \n",
       "\n",
       "         First published       Revision date  \\\n",
       "0    2019-06-07 17:00:00 2020-11-12 18:18:00   \n",
       "1    2018-08-20 00:00:00 2020-11-12 17:50:00   \n",
       "2    2017-10-27 00:00:00 2020-11-12 17:30:00   \n",
       "3    2017-10-23 00:00:00 2020-11-12 16:54:00   \n",
       "4    2018-01-08 12:30:00 2020-11-12 16:42:00   \n",
       "...                  ...                 ...   \n",
       "1730 2001-02-19 01:00:00 2001-08-01 00:00:00   \n",
       "1731 2001-01-22 01:00:00 2001-05-22 00:00:00   \n",
       "1732 1999-07-30 00:00:00 2000-12-12 01:00:00   \n",
       "1733 2000-07-27 00:00:00 2000-12-04 01:00:00   \n",
       "1734 2000-07-05 02:00:00 2000-07-17 02:00:00   \n",
       "\n",
       "                                                    URL  \n",
       "0     https://www.ema.europa.eu/en/medicines/veterin...  \n",
       "1     https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "2     https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "3     https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "4     https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "...                                                 ...  \n",
       "1730  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "1731  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "1732  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "1733  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "1734  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "\n",
       "[1735 rows x 30 columns]"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_drugs_data = ema_data = pd.read_excel('data/all_drugs_ema.xlsx', header=8)\n",
    "print(all_drugs_data['Category'].unique())\n",
    "print(all_drugs_data['Orphan medicine'].unique())\n",
    "all_drugs_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Keep only the human drugs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Medicine name</th>\n",
       "      <th>Therapeutic area</th>\n",
       "      <th>International non-proprietary name (INN) / common name</th>\n",
       "      <th>Active substance</th>\n",
       "      <th>Product number</th>\n",
       "      <th>Authorisation status</th>\n",
       "      <th>Conditional approval</th>\n",
       "      <th>Exceptional circumstances</th>\n",
       "      <th>Accelerated assessment</th>\n",
       "      <th>Orphan medicine</th>\n",
       "      <th>...</th>\n",
       "      <th>Date of refusal of marketing authorisation</th>\n",
       "      <th>Marketing authorisation holder/company name</th>\n",
       "      <th>Human pharmacotherapeutic group</th>\n",
       "      <th>Date of opinion</th>\n",
       "      <th>Decision date</th>\n",
       "      <th>Revision number</th>\n",
       "      <th>Condition / indication</th>\n",
       "      <th>First published</th>\n",
       "      <th>Revision date</th>\n",
       "      <th>URL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Cholib</td>\n",
       "      <td>Dyslipidemias</td>\n",
       "      <td>fenofibrate, simvastatin</td>\n",
       "      <td>fenofibrate, simvastatin</td>\n",
       "      <td>EMEA/H/C/002559</td>\n",
       "      <td>Authorised</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Mylan IRE Healthcare Ltd</td>\n",
       "      <td>Lipid modifying agents</td>\n",
       "      <td>2013-06-27 00:00:00</td>\n",
       "      <td>2020-10-23 00:00:00</td>\n",
       "      <td>12.0</td>\n",
       "      <td>Cholib is indicated as adjunctive therapy to d...</td>\n",
       "      <td>2018-08-20 00:00:00</td>\n",
       "      <td>2020-11-12 17:50:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Repaglinide Krka</td>\n",
       "      <td>Diabetes Mellitus, Type 2</td>\n",
       "      <td>repaglinide</td>\n",
       "      <td>repaglinide</td>\n",
       "      <td>EMEA/H/C/001066</td>\n",
       "      <td>Authorised</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Krka, d.d., Novo mesto</td>\n",
       "      <td>Drugs used in diabetes,</td>\n",
       "      <td>2009-07-23 00:00:00</td>\n",
       "      <td>2020-10-28 01:00:00</td>\n",
       "      <td>6.0</td>\n",
       "      <td>Repaglinide is indicated in patients with type...</td>\n",
       "      <td>2017-10-27 00:00:00</td>\n",
       "      <td>2020-11-12 17:30:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Liprolog</td>\n",
       "      <td>Diabetes Mellitus</td>\n",
       "      <td>insulin lispro</td>\n",
       "      <td>insulin lispro</td>\n",
       "      <td>EMEA/H/C/000393</td>\n",
       "      <td>Authorised</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Eli Lilly Nederland B.V.</td>\n",
       "      <td>Drugs used in diabetes,</td>\n",
       "      <td>2001-04-26 00:00:00</td>\n",
       "      <td>2020-09-04 00:00:00</td>\n",
       "      <td>28.0</td>\n",
       "      <td>For the treatment of adults and children with ...</td>\n",
       "      <td>2017-10-23 00:00:00</td>\n",
       "      <td>2020-11-12 16:54:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Hexacima</td>\n",
       "      <td>Hepatitis B, Tetanus, Immunization, Meningitis...</td>\n",
       "      <td>diphtheria, tetanus, pertussis (acellular, com...</td>\n",
       "      <td>diphtheria toxoid / tetanus toxoid, two-compon...</td>\n",
       "      <td>EMEA/H/C/002702</td>\n",
       "      <td>Authorised</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>2013-02-22 01:00:00</td>\n",
       "      <td>Sanofi Pasteur</td>\n",
       "      <td>Vaccines, , Bacterial and viral vaccines, comb...</td>\n",
       "      <td>2013-02-21 01:00:00</td>\n",
       "      <td>2020-09-24 00:00:00</td>\n",
       "      <td>21.0</td>\n",
       "      <td>Hexacima (DTaP-IPV-HB-Hib) is indicated for pr...</td>\n",
       "      <td>2018-01-08 12:30:00</td>\n",
       "      <td>2020-11-12 16:42:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Semglee</td>\n",
       "      <td>Diabetes Mellitus</td>\n",
       "      <td>insulin glargine</td>\n",
       "      <td>insulin glargine</td>\n",
       "      <td>EMEA/H/C/004280</td>\n",
       "      <td>Authorised</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Mylan S.A.S</td>\n",
       "      <td>Drugs used in diabetes,</td>\n",
       "      <td>2018-01-25 01:00:00</td>\n",
       "      <td>2020-10-07 00:00:00</td>\n",
       "      <td>5.0</td>\n",
       "      <td>Treatment of diabetes mellitus in adults, adol...</td>\n",
       "      <td>2018-04-03 12:07:00</td>\n",
       "      <td>2020-11-12 13:51:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1730</th>\n",
       "      <td>Liprolog</td>\n",
       "      <td>Diabetes Mellitus</td>\n",
       "      <td>insulin lispro</td>\n",
       "      <td>insulin lispro</td>\n",
       "      <td>EMEA/H/C/000143</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Eli Lilly and Company Limited</td>\n",
       "      <td>Drugs used in diabetes, , Insulins and analogu...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2001-02-19 01:00:00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>For the treatment of patients with diabetes me...</td>\n",
       "      <td>2001-02-19 01:00:00</td>\n",
       "      <td>2001-08-01 00:00:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1731</th>\n",
       "      <td>EchoGen</td>\n",
       "      <td>Echocardiography</td>\n",
       "      <td>dodecafluoropentane</td>\n",
       "      <td>dodecafluoropentane</td>\n",
       "      <td>EMEA/H/C/000149</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Sonus Pharmaceuticals Ltd.</td>\n",
       "      <td>Contrast media</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2001-01-22 01:00:00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>EchoGen is a transpulmonary echocardiographic ...</td>\n",
       "      <td>2001-01-22 01:00:00</td>\n",
       "      <td>2001-05-22 00:00:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1732</th>\n",
       "      <td>Ecokinase</td>\n",
       "      <td>Myocardial Infarction</td>\n",
       "      <td>reteplase</td>\n",
       "      <td>reteplase</td>\n",
       "      <td>EMEA/H/C/000106</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Roche Registration Ltd.</td>\n",
       "      <td>Antithrombotic agents,</td>\n",
       "      <td>NaT</td>\n",
       "      <td>1999-07-30 00:00:00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>Thrombolytic therapy of acute myocardial infar...</td>\n",
       "      <td>1999-07-30 00:00:00</td>\n",
       "      <td>2000-12-12 01:00:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1733</th>\n",
       "      <td>Primavax</td>\n",
       "      <td>Hepatitis B, Tetanus, Immunization, Diphtheria</td>\n",
       "      <td>diphtheria, tetanus and hepatitis B vaccine, a...</td>\n",
       "      <td>diphtheria toxoid purified, hepatitis B, recom...</td>\n",
       "      <td>EMEA/H/C/000156</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Pasteur Mà¨rieux MSD</td>\n",
       "      <td>Vaccines,</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2000-07-27 00:00:00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>This vaccine is indicated for active immunizat...</td>\n",
       "      <td>2000-07-27 00:00:00</td>\n",
       "      <td>2000-12-04 01:00:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1734</th>\n",
       "      <td>Pylori-Chek</td>\n",
       "      <td>Breath Tests, Helicobacter Infections</td>\n",
       "      <td>13C-urea</td>\n",
       "      <td>13C-urea</td>\n",
       "      <td>EMEA/H/C/000182</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Alimenterics B.V.</td>\n",
       "      <td>Diagnostic agents</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2000-07-05 02:00:00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>Pylori-Chek may be used for in vivo diagnosis ...</td>\n",
       "      <td>2000-07-05 02:00:00</td>\n",
       "      <td>2000-07-17 02:00:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1480 rows × 21 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         Medicine name                                   Therapeutic area  \\\n",
       "1               Cholib                                      Dyslipidemias   \n",
       "2     Repaglinide Krka                          Diabetes Mellitus, Type 2   \n",
       "3             Liprolog                                  Diabetes Mellitus   \n",
       "4             Hexacima  Hepatitis B, Tetanus, Immunization, Meningitis...   \n",
       "5              Semglee                                  Diabetes Mellitus   \n",
       "...                ...                                                ...   \n",
       "1730          Liprolog                                  Diabetes Mellitus   \n",
       "1731           EchoGen                                   Echocardiography   \n",
       "1732         Ecokinase                              Myocardial Infarction   \n",
       "1733          Primavax     Hepatitis B, Tetanus, Immunization, Diphtheria   \n",
       "1734       Pylori-Chek              Breath Tests, Helicobacter Infections   \n",
       "\n",
       "     International non-proprietary name (INN) / common name  \\\n",
       "1                              fenofibrate, simvastatin       \n",
       "2                                           repaglinide       \n",
       "3                                        insulin lispro       \n",
       "4     diphtheria, tetanus, pertussis (acellular, com...       \n",
       "5                                      insulin glargine       \n",
       "...                                                 ...       \n",
       "1730                                     insulin lispro       \n",
       "1731                                dodecafluoropentane       \n",
       "1732                                          reteplase       \n",
       "1733  diphtheria, tetanus and hepatitis B vaccine, a...       \n",
       "1734                                           13C-urea       \n",
       "\n",
       "                                       Active substance   Product number  \\\n",
       "1                              fenofibrate, simvastatin  EMEA/H/C/002559   \n",
       "2                                           repaglinide  EMEA/H/C/001066   \n",
       "3                                        insulin lispro  EMEA/H/C/000393   \n",
       "4     diphtheria toxoid / tetanus toxoid, two-compon...  EMEA/H/C/002702   \n",
       "5                                      insulin glargine  EMEA/H/C/004280   \n",
       "...                                                 ...              ...   \n",
       "1730                                     insulin lispro  EMEA/H/C/000143   \n",
       "1731                                dodecafluoropentane  EMEA/H/C/000149   \n",
       "1732                                          reteplase  EMEA/H/C/000106   \n",
       "1733  diphtheria toxoid purified, hepatitis B, recom...  EMEA/H/C/000156   \n",
       "1734                                           13C-urea  EMEA/H/C/000182   \n",
       "\n",
       "     Authorisation status Conditional approval Exceptional circumstances  \\\n",
       "1              Authorised                   no                        no   \n",
       "2              Authorised                   no                        no   \n",
       "3              Authorised                   no                        no   \n",
       "4              Authorised                   no                        no   \n",
       "5              Authorised                   no                        no   \n",
       "...                   ...                  ...                       ...   \n",
       "1730            Withdrawn                   no                        no   \n",
       "1731            Withdrawn                   no                        no   \n",
       "1732            Withdrawn                   no                        no   \n",
       "1733            Withdrawn                   no                        no   \n",
       "1734            Withdrawn                   no                        no   \n",
       "\n",
       "     Accelerated assessment Orphan medicine  ...  \\\n",
       "1                        no              no  ...   \n",
       "2                        no              no  ...   \n",
       "3                        no              no  ...   \n",
       "4                        no              no  ...   \n",
       "5                        no              no  ...   \n",
       "...                     ...             ...  ...   \n",
       "1730                     no              no  ...   \n",
       "1731                     no              no  ...   \n",
       "1732                     no              no  ...   \n",
       "1733                     no              no  ...   \n",
       "1734                     no              no  ...   \n",
       "\n",
       "     Date of refusal of marketing authorisation  \\\n",
       "1                                           NaT   \n",
       "2                                           NaT   \n",
       "3                                           NaT   \n",
       "4                           2013-02-22 01:00:00   \n",
       "5                                           NaT   \n",
       "...                                         ...   \n",
       "1730                                        NaT   \n",
       "1731                                        NaT   \n",
       "1732                                        NaT   \n",
       "1733                                        NaT   \n",
       "1734                                        NaT   \n",
       "\n",
       "     Marketing authorisation holder/company name  \\\n",
       "1                       Mylan IRE Healthcare Ltd   \n",
       "2                         Krka, d.d., Novo mesto   \n",
       "3                       Eli Lilly Nederland B.V.   \n",
       "4                                 Sanofi Pasteur   \n",
       "5                                    Mylan S.A.S   \n",
       "...                                          ...   \n",
       "1730               Eli Lilly and Company Limited   \n",
       "1731                  Sonus Pharmaceuticals Ltd.   \n",
       "1732                     Roche Registration Ltd.   \n",
       "1733                        Pasteur Mà¨rieux MSD   \n",
       "1734                           Alimenterics B.V.   \n",
       "\n",
       "                        Human pharmacotherapeutic group     Date of opinion  \\\n",
       "1                                Lipid modifying agents 2013-06-27 00:00:00   \n",
       "2                              Drugs used in diabetes,  2009-07-23 00:00:00   \n",
       "3                              Drugs used in diabetes,  2001-04-26 00:00:00   \n",
       "4     Vaccines, , Bacterial and viral vaccines, comb... 2013-02-21 01:00:00   \n",
       "5                              Drugs used in diabetes,  2018-01-25 01:00:00   \n",
       "...                                                 ...                 ...   \n",
       "1730  Drugs used in diabetes, , Insulins and analogu...                 NaT   \n",
       "1731                                     Contrast media                 NaT   \n",
       "1732                            Antithrombotic agents,                  NaT   \n",
       "1733                                         Vaccines,                  NaT   \n",
       "1734                                  Diagnostic agents                 NaT   \n",
       "\n",
       "           Decision date Revision number  \\\n",
       "1    2020-10-23 00:00:00            12.0   \n",
       "2    2020-10-28 01:00:00             6.0   \n",
       "3    2020-09-04 00:00:00            28.0   \n",
       "4    2020-09-24 00:00:00            21.0   \n",
       "5    2020-10-07 00:00:00             5.0   \n",
       "...                  ...             ...   \n",
       "1730 2001-02-19 01:00:00             0.0   \n",
       "1731 2001-01-22 01:00:00             0.0   \n",
       "1732 1999-07-30 00:00:00             0.0   \n",
       "1733 2000-07-27 00:00:00             0.0   \n",
       "1734 2000-07-05 02:00:00             0.0   \n",
       "\n",
       "                                 Condition / indication     First published  \\\n",
       "1     Cholib is indicated as adjunctive therapy to d... 2018-08-20 00:00:00   \n",
       "2     Repaglinide is indicated in patients with type... 2017-10-27 00:00:00   \n",
       "3     For the treatment of adults and children with ... 2017-10-23 00:00:00   \n",
       "4     Hexacima (DTaP-IPV-HB-Hib) is indicated for pr... 2018-01-08 12:30:00   \n",
       "5     Treatment of diabetes mellitus in adults, adol... 2018-04-03 12:07:00   \n",
       "...                                                 ...                 ...   \n",
       "1730  For the treatment of patients with diabetes me... 2001-02-19 01:00:00   \n",
       "1731  EchoGen is a transpulmonary echocardiographic ... 2001-01-22 01:00:00   \n",
       "1732  Thrombolytic therapy of acute myocardial infar... 1999-07-30 00:00:00   \n",
       "1733  This vaccine is indicated for active immunizat... 2000-07-27 00:00:00   \n",
       "1734  Pylori-Chek may be used for in vivo diagnosis ... 2000-07-05 02:00:00   \n",
       "\n",
       "           Revision date                                                URL  \n",
       "1    2020-11-12 17:50:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "2    2020-11-12 17:30:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "3    2020-11-12 16:54:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "4    2020-11-12 16:42:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "5    2020-11-12 13:51:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "...                  ...                                                ...  \n",
       "1730 2001-08-01 00:00:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "1731 2001-05-22 00:00:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "1732 2000-12-12 01:00:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "1733 2000-12-04 01:00:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "1734 2000-07-17 02:00:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "\n",
       "[1480 rows x 21 columns]"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_drugs_data = all_drugs_data[all_drugs_data['Category'] == 'Human']\n",
    "all_drugs_data = all_drugs_data.drop(columns=['Category', 'Species', 'Vet pharmacotherapeutic group', 'Additional monitoring', 'Patient safety', 'Generic', 'Biosimilar', 'ATCvet code', 'ATC code'])\n",
    "all_drugs_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Keep only orphan drugs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Medicine name</th>\n",
       "      <th>Therapeutic area</th>\n",
       "      <th>International non-proprietary name (INN) / common name</th>\n",
       "      <th>Active substance</th>\n",
       "      <th>Product number</th>\n",
       "      <th>Authorisation status</th>\n",
       "      <th>Conditional approval</th>\n",
       "      <th>Exceptional circumstances</th>\n",
       "      <th>Accelerated assessment</th>\n",
       "      <th>Orphan medicine</th>\n",
       "      <th>...</th>\n",
       "      <th>Date of refusal of marketing authorisation</th>\n",
       "      <th>Marketing authorisation holder/company name</th>\n",
       "      <th>Human pharmacotherapeutic group</th>\n",
       "      <th>Date of opinion</th>\n",
       "      <th>Decision date</th>\n",
       "      <th>Revision number</th>\n",
       "      <th>Condition / indication</th>\n",
       "      <th>First published</th>\n",
       "      <th>Revision date</th>\n",
       "      <th>URL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Xermelo</td>\n",
       "      <td>Carcinoid Tumor, Neuroendocrine Tumors</td>\n",
       "      <td>telotristat ethyl</td>\n",
       "      <td>telotristat etiprate</td>\n",
       "      <td>EMEA/H/C/003937</td>\n",
       "      <td>Authorised</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>yes</td>\n",
       "      <td>...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Ipsen Pharma</td>\n",
       "      <td>Other alimentary tract and metabolism products</td>\n",
       "      <td>2017-07-19 00:00:00</td>\n",
       "      <td>2020-11-09 01:00:00</td>\n",
       "      <td>11.0</td>\n",
       "      <td>Xermelo is indicated for the treatment of carc...</td>\n",
       "      <td>2018-04-19 12:01:00</td>\n",
       "      <td>2020-11-11 18:16:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>Zolgensma</td>\n",
       "      <td>Muscular Atrophy, Spinal</td>\n",
       "      <td>onasemnogene abeparvovec</td>\n",
       "      <td>onasemnogene abeparvovec</td>\n",
       "      <td>EMEA/H/C/004750</td>\n",
       "      <td>Authorised</td>\n",
       "      <td>yes</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>yes</td>\n",
       "      <td>...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Novartis Gene Therapies EU Limited</td>\n",
       "      <td>Other drugs for disorders of the musculo-skele...</td>\n",
       "      <td>2020-03-26 01:00:00</td>\n",
       "      <td>2020-10-15 00:00:00</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Zolgensma is indicated for the treatment of:, ...</td>\n",
       "      <td>2020-05-27 15:00:00</td>\n",
       "      <td>2020-11-09 17:56:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>Ayvakyt</td>\n",
       "      <td>Gastrointestinal Stromal Tumors</td>\n",
       "      <td>avapritinib</td>\n",
       "      <td>avapritinib</td>\n",
       "      <td>EMEA/H/C/005208</td>\n",
       "      <td>Authorised</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>yes</td>\n",
       "      <td>...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Blueprint Medicines (Netherlands) B.V.</td>\n",
       "      <td>Other antineoplastic agents, Protein kinase in...</td>\n",
       "      <td>2020-07-23 00:00:00</td>\n",
       "      <td>2020-10-15 00:00:00</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Ayvakyt is indicated as monotherapy for the tr...</td>\n",
       "      <td>2020-09-30 09:30:00</td>\n",
       "      <td>2020-11-06 17:28:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>Zejula</td>\n",
       "      <td>Fallopian Tube Neoplasms, Peritoneal Neoplasms...</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>Niraparib (tosylate monohydrate)</td>\n",
       "      <td>EMEA/H/C/004249</td>\n",
       "      <td>Authorised</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>yes</td>\n",
       "      <td>...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>GlaxoSmithKline (Ireland) Limited</td>\n",
       "      <td>Antineoplastic agents,</td>\n",
       "      <td>2017-09-14 00:00:00</td>\n",
       "      <td>2020-10-27 01:00:00</td>\n",
       "      <td>11.0</td>\n",
       "      <td>Zejula is indicated:, , as monotherapy for the...</td>\n",
       "      <td>2017-12-19 17:47:00</td>\n",
       "      <td>2020-11-06 15:49:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>Defitelio</td>\n",
       "      <td>Hepatic Veno-Occlusive Disease</td>\n",
       "      <td>defibrotide</td>\n",
       "      <td>defibrotide</td>\n",
       "      <td>EMEA/H/C/002393</td>\n",
       "      <td>Authorised</td>\n",
       "      <td>no</td>\n",
       "      <td>yes</td>\n",
       "      <td>no</td>\n",
       "      <td>yes</td>\n",
       "      <td>...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Gentium S.r.l.</td>\n",
       "      <td>Antithrombotic agents,</td>\n",
       "      <td>2013-07-25 00:00:00</td>\n",
       "      <td>2020-10-14 00:00:00</td>\n",
       "      <td>12.0</td>\n",
       "      <td>Defitelio is indicated for the treatment of se...</td>\n",
       "      <td>2017-04-21 12:12:00</td>\n",
       "      <td>2020-11-05 17:16:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1585</th>\n",
       "      <td>Istodax</td>\n",
       "      <td>Lymphoma, Non-Hodgkin</td>\n",
       "      <td>romidepsin</td>\n",
       "      <td>romidepsin</td>\n",
       "      <td>EMEA/H/C/002122</td>\n",
       "      <td>Refused</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>yes</td>\n",
       "      <td>...</td>\n",
       "      <td>2013-02-12 01:00:00</td>\n",
       "      <td>Celgene Europe Ltd.</td>\n",
       "      <td>Antineoplastic agents,</td>\n",
       "      <td>2012-11-15 01:00:00</td>\n",
       "      <td>2012-07-20 00:00:00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>treatment of peripheral T-cell lymphoma (PTCL),</td>\n",
       "      <td>2012-07-20 15:02:00</td>\n",
       "      <td>2013-03-14 10:08:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1590</th>\n",
       "      <td>Elelyso</td>\n",
       "      <td>Gaucher Disease</td>\n",
       "      <td>taliglucerase alfa</td>\n",
       "      <td>Taliglucerase alfa</td>\n",
       "      <td>EMEA/H/C/002250</td>\n",
       "      <td>Refused</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>yes</td>\n",
       "      <td>...</td>\n",
       "      <td>2012-10-25 00:00:00</td>\n",
       "      <td>Pfizer Ltd.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2012-07-03 00:00:00</td>\n",
       "      <td>2012-10-29 01:00:00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>treatment of Gaucher disease,</td>\n",
       "      <td>2012-10-29 13:07:00</td>\n",
       "      <td>2012-11-23 15:34:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1610</th>\n",
       "      <td>Folotyn</td>\n",
       "      <td>Lymphoma, T-Cell</td>\n",
       "      <td>pralatrexate</td>\n",
       "      <td>Pralatrexate</td>\n",
       "      <td>EMEA/H/C/002096</td>\n",
       "      <td>Refused</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>yes</td>\n",
       "      <td>...</td>\n",
       "      <td>2012-06-21 00:00:00</td>\n",
       "      <td>Allos Therapeutics Ltd</td>\n",
       "      <td>Antineoplastic agents,</td>\n",
       "      <td>2012-04-19 00:00:00</td>\n",
       "      <td>2012-01-20 01:00:00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>treatment of peripheral T-cell lymphoma,</td>\n",
       "      <td>2012-01-20 13:03:00</td>\n",
       "      <td>2012-07-11 10:05:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1652</th>\n",
       "      <td>Sovrima</td>\n",
       "      <td>Friedreich Ataxia</td>\n",
       "      <td>idebenone</td>\n",
       "      <td>idebenone</td>\n",
       "      <td>EMEA/H/C/000908</td>\n",
       "      <td>Refused</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>yes</td>\n",
       "      <td>...</td>\n",
       "      <td>2009-04-27 00:00:00</td>\n",
       "      <td>Centocor B.V.</td>\n",
       "      <td>Psychoanaleptics,</td>\n",
       "      <td>2008-11-20 01:00:00</td>\n",
       "      <td>2009-12-31 01:00:00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>Treatment of Friedreichâs Ataxia</td>\n",
       "      <td>2009-12-31 02:00:00</td>\n",
       "      <td>2009-12-31 02:00:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1694</th>\n",
       "      <td>Mylotarg</td>\n",
       "      <td>Leukemia, Myeloid, Acute</td>\n",
       "      <td>gemtuzumab ozogamicin</td>\n",
       "      <td>gemtuzumab ozogamicin</td>\n",
       "      <td>EMEA/H/C/000705</td>\n",
       "      <td>Refused</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>no</td>\n",
       "      <td>yes</td>\n",
       "      <td>...</td>\n",
       "      <td>2008-04-14 00:00:00</td>\n",
       "      <td>Wyeth Europa Ltd</td>\n",
       "      <td>Antineoplastic agents,</td>\n",
       "      <td>2008-01-24 01:00:00</td>\n",
       "      <td>2008-01-24 01:00:00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>re-induction treatment of CD33-positive AML ad...</td>\n",
       "      <td>2008-01-24 01:00:00</td>\n",
       "      <td>2008-01-24 01:00:00</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>126 rows × 21 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Medicine name                                   Therapeutic area  \\\n",
       "14         Xermelo             Carcinoid Tumor, Neuroendocrine Tumors   \n",
       "30       Zolgensma                           Muscular Atrophy, Spinal   \n",
       "36         Ayvakyt                    Gastrointestinal Stromal Tumors   \n",
       "40          Zejula  Fallopian Tube Neoplasms, Peritoneal Neoplasms...   \n",
       "43       Defitelio                     Hepatic Veno-Occlusive Disease   \n",
       "...            ...                                                ...   \n",
       "1585       Istodax                              Lymphoma, Non-Hodgkin   \n",
       "1590       Elelyso                                    Gaucher Disease   \n",
       "1610       Folotyn                                   Lymphoma, T-Cell   \n",
       "1652       Sovrima                                  Friedreich Ataxia   \n",
       "1694      Mylotarg                           Leukemia, Myeloid, Acute   \n",
       "\n",
       "     International non-proprietary name (INN) / common name  \\\n",
       "14                                    telotristat ethyl       \n",
       "30                             onasemnogene abeparvovec       \n",
       "36                                          avapritinib       \n",
       "40                                            niraparib       \n",
       "43                                          defibrotide       \n",
       "...                                                 ...       \n",
       "1585                                         romidepsin       \n",
       "1590                                 taliglucerase alfa       \n",
       "1610                                       pralatrexate       \n",
       "1652                                          idebenone       \n",
       "1694                              gemtuzumab ozogamicin       \n",
       "\n",
       "                      Active substance   Product number Authorisation status  \\\n",
       "14                telotristat etiprate  EMEA/H/C/003937           Authorised   \n",
       "30            onasemnogene abeparvovec  EMEA/H/C/004750           Authorised   \n",
       "36                         avapritinib  EMEA/H/C/005208           Authorised   \n",
       "40    Niraparib (tosylate monohydrate)  EMEA/H/C/004249           Authorised   \n",
       "43                         defibrotide  EMEA/H/C/002393           Authorised   \n",
       "...                                ...              ...                  ...   \n",
       "1585                        romidepsin  EMEA/H/C/002122              Refused   \n",
       "1590                Taliglucerase alfa  EMEA/H/C/002250              Refused   \n",
       "1610                      Pralatrexate  EMEA/H/C/002096              Refused   \n",
       "1652                         idebenone  EMEA/H/C/000908              Refused   \n",
       "1694             gemtuzumab ozogamicin  EMEA/H/C/000705              Refused   \n",
       "\n",
       "     Conditional approval Exceptional circumstances Accelerated assessment  \\\n",
       "14                     no                        no                     no   \n",
       "30                    yes                        no                     no   \n",
       "36                     no                        no                     no   \n",
       "40                     no                        no                     no   \n",
       "43                     no                       yes                     no   \n",
       "...                   ...                       ...                    ...   \n",
       "1585                   no                        no                     no   \n",
       "1590                   no                        no                     no   \n",
       "1610                   no                        no                     no   \n",
       "1652                   no                        no                     no   \n",
       "1694                   no                        no                     no   \n",
       "\n",
       "     Orphan medicine  ... Date of refusal of marketing authorisation  \\\n",
       "14               yes  ...                                        NaT   \n",
       "30               yes  ...                                        NaT   \n",
       "36               yes  ...                                        NaT   \n",
       "40               yes  ...                                        NaT   \n",
       "43               yes  ...                                        NaT   \n",
       "...              ...  ...                                        ...   \n",
       "1585             yes  ...                        2013-02-12 01:00:00   \n",
       "1590             yes  ...                        2012-10-25 00:00:00   \n",
       "1610             yes  ...                        2012-06-21 00:00:00   \n",
       "1652             yes  ...                        2009-04-27 00:00:00   \n",
       "1694             yes  ...                        2008-04-14 00:00:00   \n",
       "\n",
       "     Marketing authorisation holder/company name  \\\n",
       "14                                  Ipsen Pharma   \n",
       "30            Novartis Gene Therapies EU Limited   \n",
       "36        Blueprint Medicines (Netherlands) B.V.   \n",
       "40             GlaxoSmithKline (Ireland) Limited   \n",
       "43                                Gentium S.r.l.   \n",
       "...                                          ...   \n",
       "1585                         Celgene Europe Ltd.   \n",
       "1590                              Pfizer Ltd.      \n",
       "1610                      Allos Therapeutics Ltd   \n",
       "1652                               Centocor B.V.   \n",
       "1694                            Wyeth Europa Ltd   \n",
       "\n",
       "                        Human pharmacotherapeutic group     Date of opinion  \\\n",
       "14       Other alimentary tract and metabolism products 2017-07-19 00:00:00   \n",
       "30    Other drugs for disorders of the musculo-skele... 2020-03-26 01:00:00   \n",
       "36    Other antineoplastic agents, Protein kinase in... 2020-07-23 00:00:00   \n",
       "40                              Antineoplastic agents,  2017-09-14 00:00:00   \n",
       "43                              Antithrombotic agents,  2013-07-25 00:00:00   \n",
       "...                                                 ...                 ...   \n",
       "1585                            Antineoplastic agents,  2012-11-15 01:00:00   \n",
       "1590                                                NaN 2012-07-03 00:00:00   \n",
       "1610                            Antineoplastic agents,  2012-04-19 00:00:00   \n",
       "1652                                 Psychoanaleptics,  2008-11-20 01:00:00   \n",
       "1694                            Antineoplastic agents,  2008-01-24 01:00:00   \n",
       "\n",
       "           Decision date Revision number  \\\n",
       "14   2020-11-09 01:00:00            11.0   \n",
       "30   2020-10-15 00:00:00             1.0   \n",
       "36   2020-10-15 00:00:00             1.0   \n",
       "40   2020-10-27 01:00:00            11.0   \n",
       "43   2020-10-14 00:00:00            12.0   \n",
       "...                  ...             ...   \n",
       "1585 2012-07-20 00:00:00             0.0   \n",
       "1590 2012-10-29 01:00:00             0.0   \n",
       "1610 2012-01-20 01:00:00             0.0   \n",
       "1652 2009-12-31 01:00:00             0.0   \n",
       "1694 2008-01-24 01:00:00             0.0   \n",
       "\n",
       "                                 Condition / indication     First published  \\\n",
       "14    Xermelo is indicated for the treatment of carc... 2018-04-19 12:01:00   \n",
       "30    Zolgensma is indicated for the treatment of:, ... 2020-05-27 15:00:00   \n",
       "36    Ayvakyt is indicated as monotherapy for the tr... 2020-09-30 09:30:00   \n",
       "40    Zejula is indicated:, , as monotherapy for the... 2017-12-19 17:47:00   \n",
       "43    Defitelio is indicated for the treatment of se... 2017-04-21 12:12:00   \n",
       "...                                                 ...                 ...   \n",
       "1585   treatment of peripheral T-cell lymphoma (PTCL),  2012-07-20 15:02:00   \n",
       "1590                     treatment of Gaucher disease,  2012-10-29 13:07:00   \n",
       "1610          treatment of peripheral T-cell lymphoma,  2012-01-20 13:03:00   \n",
       "1652                 Treatment of Friedreichâs Ataxia 2009-12-31 02:00:00   \n",
       "1694  re-induction treatment of CD33-positive AML ad... 2008-01-24 01:00:00   \n",
       "\n",
       "           Revision date                                                URL  \n",
       "14   2020-11-11 18:16:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "30   2020-11-09 17:56:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "36   2020-11-06 17:28:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "40   2020-11-06 15:49:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "43   2020-11-05 17:16:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "...                  ...                                                ...  \n",
       "1585 2013-03-14 10:08:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "1590 2012-11-23 15:34:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "1610 2012-07-11 10:05:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "1652 2009-12-31 02:00:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "1694 2008-01-24 01:00:00  https://www.ema.europa.eu/en/medicines/human/E...  \n",
       "\n",
       "[126 rows x 21 columns]"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_drugs_data = all_drugs_data[all_drugs_data['Orphan medicine'] == 'yes']\n",
    "all_drugs_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### How many authorised orphan drugs are there?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "111"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(all_drugs_data[all_drugs_data['Authorisation status'] == 'Authorised'])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "There are way fewer orphan drugs than orphan drug designations (Active substance)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### How many unique Active substances?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1373"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "unique_active_substances = matched_data['Active substance'].unique()\n",
    "len(unique_active_substances)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### How many designation does each substance have?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Active Substance</th>\n",
       "      <th>Number designations</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>miltefosine</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>antisense oligonucleotide (tatccggagggctcgccat...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>recombinant antibody derivative against human ...</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>n-(methyl-diazacyclohexyl-methylbenzamide)-aza...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>midostaurin</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>183</th>\n",
       "      <td>6,8-bis(benzylthio)octanoic acid</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>184</th>\n",
       "      <td>rozanolixizumab</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>185</th>\n",
       "      <td>allogeneic cultured postnatal thymus-derived t...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>186</th>\n",
       "      <td>sodium benzoate, sodium phenylacetate</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>187</th>\n",
       "      <td>reldesemtiv</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>188 rows × 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                      Active Substance  Number designations\n",
       "0                                          miltefosine                    3\n",
       "1    antisense oligonucleotide (tatccggagggctcgccat...                    3\n",
       "2    recombinant antibody derivative against human ...                    2\n",
       "3    n-(methyl-diazacyclohexyl-methylbenzamide)-aza...                    3\n",
       "4                                          midostaurin                    2\n",
       "..                                                 ...                  ...\n",
       "183                   6,8-bis(benzylthio)octanoic acid                    2\n",
       "184                                    rozanolixizumab                    2\n",
       "185  allogeneic cultured postnatal thymus-derived t...                    3\n",
       "186              sodium benzoate, sodium phenylacetate                    2\n",
       "187                                        reldesemtiv                    2\n",
       "\n",
       "[188 rows x 2 columns]"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "names = []\n",
    "number_designations = []\n",
    "for substance in unique_active_substances:\n",
    "    mask = matched_data['Active substance'] == substance\n",
    "    designations = matched_data['Active substance'][mask]\n",
    "    number = len(designations)\n",
    "    \n",
    "    if number > 1:\n",
    "        names.append(substance)\n",
    "        number_designations.append(number)\n",
    "        \n",
    "df_number_designations = pd.DataFrame({'Active Substance': names, 'Number designations': number_designations})\n",
    "df_number_designations"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### What is the maximum number of designations"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([ 3,  2,  4,  6,  5,  7,  9, 12])"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_number_designations['Number designations'].unique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Active Substance</th>\n",
       "      <th>Number designations</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>144</th>\n",
       "      <td>sodium benzoate</td>\n",
       "      <td>12</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    Active Substance  Number designations\n",
       "144  sodium benzoate                   12"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_number_designations[df_number_designations['Number designations'] == 12]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "erlotinib-venv",
   "language": "python",
   "name": "erlotinib-venv"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
